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ABSTRACT
Drug-induced liver injury (DILI) is one of the leading reasons for clinical
candidate termination during drug discovery and development. Similarly, many drugs
have received a black-box warning or withdrawn from the market due to DILI. It is
reported that DILI is the 4th leading cause of liver disease leading to liver failure. It is
estimated that the DILI has an annual incidence rate of 13.9 ± 2.4 cases per 100,000
people, translating to about 44,000 liver injury patients in the United States each year.
Despite tremendous research in the predictive field, liver injury prediction using in vitro
and in vivo models remains a substantial challenge. In this dissertation, I use the threemanuscript format to address the literature gap based on the drug's toxicological
properties and its ability to cause mitochondrial dysfunction. I also evaluated the risk of
liver injury among patients newly treated with atypical antipsychotics.
Manuscript 1 combined physicochemical properties and in vitro cytotoxicity
assays, including mitochondrial dysfunction, to build organ-specific univariate and
multivariable logistic regression models to derive odds ratios for the prediction of clinical
hepatotoxicity, nephrotoxicity, and cardiotoxicity for 215 marketed drugs.

The

multivariable hepatotoxic predictive model showed an odds ratio of 6.2 or 7.5 for
mitochondrial inhibition or drug plasma Cmax >1 µM for drugs associated with liver
injury, respectively. The multivariable nephrotoxicity predictive model showed an odds
ratio of 5.8, 6.4, or 15.9 for drug plasma Cmax >1 µM, mitochondrial inhibition, or
hydrogen bond acceptor atoms greater than 7 for drugs associated with kidney injury,
respectively. Conversely, drugs with a total polar surface area ≥75Å were 79% less
likely to be associated with kidney injury. Based on this study, I found that combining
in silico physicochemical properties descriptors along with in vitro toxicity assays can
be used to build predictive toxicity models to select small molecule therapeutics with

less potential to cause liver and kidney toxicity. Therefore, I recommend a blended
approach of utilizing readily calculated physicochemical properties combined with in
vitro toxicity assessments to select small molecules with less potential for clinical organ
toxicity for the liver and kidney.
There is a growing need for characterization of age-differences in the
susceptibility and frequency of DILI caused by hepatotoxicants according to their ability
to cause mitochondrial dysfunction. Manuscript 2 investigated the relationship between
liver injury reports submitted to the Food and Drug Administration Adverse Event
Reporting System with drugs associated with hepatotoxicity via mitochondrial
mechanisms compared with non-mitochondrial mechanisms of toxicity. This study
provides evidence that a higher proportion of reports of severe liver injury adverse
events among drugs are associated with mitochondrial mechanisms of toxicity
compared with non-mitochondrial mechanisms of toxicity. Furthermore, I found that
reports of liver injury were 2.2 times more likely to be associated with older patient age
than reports involving patients ages under 65 years. This finding agreed with the theory
that age is a susceptibility factor in liver injury via mitochondrial mechanisms of toxicity.
The findings from this study align with mitochondrial mechanisms of toxicity being an
important cause of DILI, and this should be further investigated in real-world studies
with robust designs.
Compared to typical antipsychotics, atypical antipsychotics (AAP) medications
have improved safety profiles and rarely cause liver injury. However, no retrospective
cohort studies have evaluated AAP's liver injury risk using an administrative database
in the United States. In manuscript 3, I conducted a retrospective cohort study using
an administrative claims database to estimate the cumulative incidence rate and
identify risk factors for liver injury in patients taking AAP medications. Univariate and
multivariate logistic regression analyses were utilized to identify risk factors associated

with liver injury. The study estimated the cumulative incidence rate of liver injury 15.2
to 25.1 per 1000 persons per year among patients newly treated with AAP medications.
During the first months of treatment, quetiapine, as compared to aripiprazole, was
associated with a 22% increased risk of liver injury in patients 75 years and younger.
Our study suggests that patients receiving quetiapine AAP should be monitored for liver
enzyme elevations frequently during therapy initiation. Patients with comorbidities
including alcohol abuse, hypertension, obesity, and hyperlipidemia were also found to
be at higher risk and these patients should be monitored closely for liver injury. Further
prospective real-world studies are warranted to substantiate these findings.
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PREFACE
This dissertation is written in the three-manuscript format and formatted based
on the guideline provided by the University of Rhode Island Graduate School. These
three manuscripts encompassed important aspects of Drug-induced liver injury: most
influential descriptors for a predictive model (manuscript I), mitochondrial toxicity
mechanism risk (manuscript II), and liver injury among patients newly treated with
atypical antipsychotics mediations (manuscript III).
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1.1 ABSTRACT
Drug-induced organ injury is a major reason for drug candidate attrition in preclinical
and clinical drug development. The liver, kidneys, and heart have been recognized as
the most common organ systems affected in safety-related attrition or the subject of
black box warnings, and post-market drug withdrawals. In silico physicochemical
property calculations and in vitro assays have been utilized separately in the early
stages of the drug discovery and development process to predict drug safety. In this
study, we combined physicochemical properties and in vitro cytotoxicity assays
including mitochondrial dysfunction to build organ-specific univariate and multivariable
logistic regression models to derive odds ratios for the prediction of clinical
hepatotoxicity, nephrotoxicity, and cardiotoxicity for 215 marketed oral drugs. The
multivariable hepatotoxic predictive model showed an odds ratio of 6.2 (95%
Confidence Interval (CI)-1.7-22.8) or 7.5 (95% CI-3.2-17.8) for mitochondrial inhibition
or drug plasma Cmax >1 µM for drugs associated with liver injury, respectively. The
multivariable nephrotoxicity predictive model showed an odds ratio of 5.8 (95% CI-2.016.9), 6.4 (95% CI-1.1-39.3), or 15.9 (95% CI-2.8-89.0) for drug plasma Cmax >1 µM,
mitochondrial inhibition, or hydrogen bond acceptor atoms greater than 7 for drugs
associated with kidney injury, respectively. Conversely, drugs with a total polar surface
area ≥75Å were 79% (odds ratio 0.21, 95% CI-0.061-0.74) less likely to be associated
with kidney injury. Drugs belonging to the Extended Clearance Classification System
(ECCS) class 4, where renal secretion is the primary clearance mechanism (low
permeability drugs that are bases/neutrals), were 4 (95% CI-1.8-9.5) times more likely
to cause kidney injury with this data set. Alternatively, ECCS class 2 drugs, where
hepatic metabolism is the primary clearance (high permeability drugs that are
bases/neutrals), were 77% less likely (odds ratio 0.23 95%CI-0.095-0.54) to cause
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kidney injury. A cardiotoxicity model was poorly defined using any of these drug
physicochemical attributes. Combining in silico physicochemical properties descriptors
along with in vitro toxicity assays can be used to build predictive toxicity models to
select small molecule therapeutics with less potential to cause liver and kidney organ
toxicity.
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1.2 INTRODUCTION
The high rate of safety-related attrition and the enormous cost of developing
new drugs have encouraged the pharmaceutical industry to move safety evaluation
earlier into the drug discovery process when structure-toxicity relationship
determination is feasible.1 This can be easily done before more expensive toxicity
testing is conducted in small (rodent) and large (non-rodent) animal species an
advance of clinical trials that may ultimately be poorly predictive of human druginduced organ injury.2-4

Hence, various in silico tools, such as structural alerts,

physicochemical properties,5-7 and in vitro toxicity assays8, 9 have been proposed to
accelerate drug development with adequate safety and at a lower cost.
The association of physicochemical properties with animal and human toxicity
has been widely accepted and published in the literature.10-14

Hughes et al.

demonstrated that highly lipophilic, less polar drug candidates are more likely to cause
safety issues in animal exploratory toxicity studies using 245 small molecules.10 The
utilization of physicochemical properties combined with general cytotoxicity assays to
progress potential clinical candidates into animal toxicity studies has been explored.1113

For human liver organ toxicity, Leeson (2018) successfully utilized physicochemical

properties to predict "Most-DILI-" from "No-DILI-"concern drugs in 1841 marketed
small molecule therapeutic drugs.14 The author demonstrated high value of lipophilicity
and fraction of carbon atoms that are sp3 hybridized (Fsp3) when combined with
maximum applied daily dose for separating these binary (categorical) predictions of
human liver toxicity.14
There has been utilization of absorption, distribution, metabolism, elimination
(ADME) drug attributes in the prediction of human DILI as well.15-20 Some researchers
have analyzed DILI relationships based on the Biopharmaceutics Drug Disposition
Classification System (BDDCS), a method used to predict the drug disposition as well
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as potential drug-drug interactions (DDI).15-17 As expected, the majority of drugs that
cause human DILI undergo extensive hepatic metabolism18 and, in the absence of
knowledge of an applied daily dose, it was suggested that avoiding the development
of BDDCS class 2 molecules (low solubility, extensive mechanism) could be used to
prevent clinical DILI.19

Using this approach, Chan et al. stated there was little

additional value in adding in vitro toxicity assays over the BDDCS classification
system.20 Similar to BDDCS classification, some researchers have utilized the
Extended Clearance Classification System (ECCS) for early predictions of ratedetermining clearance mechanisms.21 ECCS has been utilized to understand ADME
attributes, and enabling victim DDI predictions in chemical design and molecule
selection.22
From a biological perspective, several assays related to hepatotoxicity have
also been used for predictions.23 These involve measurements of cytotoxicity, or
mitochondrial dysfunction, and/or bile acid efflux inhibition.23 Some studies have
utilized mitochondrial toxicity assessments alone24 or in combination with other assays
to highlight drugs of Most-DILI-concern.25 Although, these approaches have been
useful in highlighting drugs with Most-DILI-concern potential, neither of these later
approaches considered the value of combining physicochemical properties, or ECCS
classifications, with relevant in vitro mechanistic assays.
Aleo et al. recently showed the value of combining major physicochemical
properties with in vitro assays relevant to liver safety for discriminating DILI compounds
across and within categories of liver injury (Most-, Less- and No-DILI-concern) along
with their FDA label for liver safety (no mention, adverse reactions, warnings and
precautions, black box warnings and withdrawn).26 This hybrid approach offered value
for new chemical entities in clinical development that were discontinued for significant
liver transaminase elevations. With this success, however, we believe considerable
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efforts should be made to develop better predictive models of clinical organ toxicity
beyond the liver. To our knowledge, there is a significant gap in the literature for
integrating both physicochemical properties with in vitro mechanistic assays for
predicting major organ system toxicities beyond the liver, such as kidney and heart.
Because mitochondrial dysfunction is a universal safety concern across
multiple organ systems, the utilization of mitochondrial toxicity assays and
physicochemical properties for the prediction of organ toxicity was explored by Rana
et al. using 228 drugs.27 It was concluded that testing drugs in mitochondrial assays
at 100 times the maximum total plasma concentration (Cmax) provided the highest
sensitivity for predicting hepatotoxicity. Furthermore, in-depth physicochemical
properties space was explored for the drugs that were positive in the mitochondrial
assays compared with those that were tested negative. Drugs testing positive in
mitochondrial assays possessed different physicochemical properties in terms of
lipophilicity and were prone to be in either acid or neutral ionization states compared
with drugs that tested negative.27 In this study, we proposed to expand the concept of
combining physicochemical properties with in vitro assays to explore the major organ
system toxicity other than hepatotoxicity. Furthermore, we expanded the combination
of the most predictable characteristics of in vitro assays and physicochemical
properties to build human organ toxicity predictive models using univariate and
multivariable logistic regression modeling. We hypothesized that there are different
sets of in vitro assays, and physicochemical properties can be predictive of toxicity in
selected organs (liver, kidney, and heart). We examined this relationship quantitatively
using the odds ratio for the prediction of clinical organ toxicity.
The overall goal of this study is to help build better predictive models for
hepatotoxicity, nephrotoxicity, and cardiotoxicity using the least number of input
variables necessary for discrimination to optimize the process for efficiency and cost
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savings. Drug physicochemical properties (hydrogen bond donor and acceptor count,
Fsp3, calculated log partition coefficient (cLogP), total polar surface area (TPSA),
molecular weight (MW), and Cmax values), ECCS class, and effects using in vitro
mechanistic assays (Transformed Human Liver Epithelial (THLE) cytotoxicity assays,
glucose/galactose assays, and mitochondrial respiration inhibitory/uncoupling assays)
of 215 pharmaceutical drugs were investigated via utilization of multivariable logistic
regression methods.
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1.3 METHODS
Data Source
The physicochemical properties, ECCS classes, and in vitro results of the
marketed drugs were utilized from previously published methods.21, 27-32 The in vitro
assay results were previously published by Rana et al. or Shah et al.13, 23, 27
Inclusion criteria for the drugs
The present study included 215 drugs (70 hepatotoxic drugs, 44 cardiotoxic
drugs, 45 nephrotoxic drugs, and 56 drugs not known to cause human organ toxicity).
These drugs were small molecules, represented diverse target pharmacology, and
belonged to multiple indications and therapeutic areas. Hepatotoxic drugs and drugs
not known to have organ toxicity (Most-, Less- and No-DILI-concern) were annotated
using the United States National Center for Toxicological Research Liver Toxicity
Knowledge Base (NCTR-LTKB). 33, 34 Nephrotoxic and cardiotoxic drug classification
were adapted from previously published literatures from Lin and Will, and Rana et al.27,
30

Lin and Will (2012) classified nephrotoxic and cardiotoxic drugs via automated

queries from published literature on drug-induced toxicity; this information was curated
manually.27 All the compounds selected for three categories of organ toxicity were
reported in the previous publications or had literature evidence of specific organ black
box warning or withdrawal.13, 23, 27, 30, 35
To build a separate model for each organ toxicity group using a univariate and
multivariable logistic regression model, a drug was classified as either positive (1) or
negative (0) outcome of organ toxicity.36 For drugs where multiple papers reported
two or more organ toxicities, drug adverse event counts (using FAERS database) were
utilized to include a drug in one organ toxicity category. The method of calculating
drug adverse event counts has been described previously.27, 37
Selection of independent variables

8

Medicinal chemists in the pharmaceutical industry have utilized Lipinski’s Rule
of 5 as the first step to eliminate molecules with poor physicochemical properties for
oral bioavailability.38

More recently, ECCS computational modeling has been

employed to facilitate the early assessment of the rate-determining step in drug
clearance, pharmacokinetic variability, and proposed metabolism/excretion pathway
based on basic physicochemical properties and passive membrane permeability
assessments.21, 22 This differs slightly from estimates of BDDCS classification, which
focuses on the extent of drug elimination and solubility.21
Physicochemical properties such as TPSA and cLogP are indicative of drug
polarity and lipophilicity. Drugs with high lipophilicity and low polarity (cLogP≥3 and
TPSA<75 Å2) had significantly increased toxic outcomes in animal studies compared
with drugs that had both lower lipophilicity and higher polarity (cLogP<3 and
TPSA≥75 Å2).10, 12, 39 Along with higher lipophilicity, lower Fsp3 has been reported with
predicting drugs with high potential of liver injury.14 MW is essential in demonstrating
on- and off-target drug toxicity.13 MW greater than 400 Da has been associated with
toxicity and considered as a less desirable characteristic in an orally administered
drug.14,

21

A previous study reported that reducing the number of heteroatoms,

especially hydrogen-bond donors and acceptors, has been used to decrease Pglycoprotein transporter efflux.40 The hydrogen bond donor (greater than 5) and
acceptor (greater than 7) counts have been used for optimal drug exposure.39 Finally,
drugs with higher Cmax have been demonstrated in several studies with a higher risk
of organ injury.14, 23, 27, 41
This study utilized Respirometric Screening Technology (RST), a high
throughput screening mitochondrial assay that has been used to measure effects on
respiration (inhibition or uncoupling) in isolated rat liver mitochondria along with cellular
assessments of mitochondrial toxicity. Mitochondrial dysfunction at the cellular level
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was determined using the previously published glucose/galactose model.28,

31, 42-44

Furthermore, this study also included a general cytotoxicity assay that measures the
effect of a compound on Transformed Human Liver Epithelial (THLE) cells viability.
This assay has been reported for being a valuable tool to select compounds for
progression into in vivo studies.12, 13
In the present study, we have used independent variables including
physicochemical properties (hydrogen bond donor & acceptor count, Fsp3, cLogP,
TPSA, MW, and Cmax values) and in vitro assay results (THLE cytotoxicity assay,
glucose/galactose assays, and mitochondrial respiration inhibitory/uncoupling assays)
to develop predictive models for liver, kidney, and heart organ toxicity. The study
further incorporated the ECCS based on clearance, metabolism, permeability, and drug
ionization states to evaluate their association with the organ toxicity group.
Dependent variable
For this study, the dependent variable was whether a drug was associated with
an increased risk of hepatotoxicity, nephrotoxicity, or cardiotoxicity (yes or no).
Statistical Analysis
This study intended to use binary outcome models to build separate predictive
models for each organ toxicity drug group. There has been evidence in the literature
for utilizing this approach to develop risk based adjustment models.36 Each toxic drug
group (hepatotoxic, nephrotoxic, and cardiotoxic) was compared against a no organ
toxic drug group. The differences in the continuous variables of drug characteristics
between the comparison groups were assessed using the Student t-test for
independent samples. All continuous variables were dichotomized using clinicallyrelevant criteria available in the literature (as shown in Table 1). Collinearity among
independent variables was assessed by examining variance inflation factors, condition
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indices, and variance proportions. Highly correlated variables were identified, and the
less important variables were removed from further inclusion in univariate and
multivariable logistic regression modeling.
The study first specified a univariate logistic regression model for each toxicity
group (against no organ toxic group) and calculated the odds ratios, 95% confidence
intervals, and p-values. The p-values less than 0.2 (less stringent with 80% probability
of association) in the univariate logistic regression models were included for further
multivariable logistic regression analyses. Afterward, a stepwise multivariable logistic
regression model via backward elimination was utilized to choose the most predictive
variables after removing insignificant variables. The odds ratios for final fitted models,
95% confidence intervals, and p-values were calculated in this multivariable logistic
regression model after removing the insignificant variables with p ≥ 0.2. The univariate
analysis evaluated the unadjusted association between organ toxicity outcome and a
single variable.

In contrast, the multivariable analysis assessed the adjusted

association between organ toxicity outcome with several variables simultaneously.45
The Hosmer and Lemeshow goodness-of-fit test was performed to determine if
the model fit adequately, where p > 0.05 indicated that the model fit appropriately.45
The AUC-ROC (Area Under Curve – Receiving Operating Curve) method was used to
evaluate performances of different predictive models, and to identify the optimized
model with the most influential predictors of the organ toxic drugs. AUC-ROC is a plot
of sensitivity vs. 1-specificity.46 AUC-ROC evaluates the discrimination power of the
model; an AUC-ROC value close to 1 suggests that selected variables were able to
separate organ toxic drugs from no organ toxic drugs. Whereas, an AUC-ROC value
close to 0.5 indicates that selected variables were not able to separate organ toxic
drugs from no organ toxic drugs. All analyses were performed with SAS version 9.4
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(SAS Institute, Cary, NC), and all statistical tests were two-sided with a significance
level at 0.05.
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1.4 RESULTS
Characteristics of physicochemical properties and in vitro assay results of organ
toxicity drugs
The physicochemical properties (hydrogen bond donor and acceptor count,
Fsp3, cLogP, TPSA, MW, and Cmax values) and in vitro assay results (THLE
cytotoxicity assay, glucose/galactose assays, and RST mitochondrial respiration
inhibitory/uncoupling assays) of each organ toxicity drug groups were compared with
the no organ toxicity group (Table 2). For hepatotoxic drugs, there was a statistically
significant (p-value < 0.05) difference for Cmax, THLE cytotoxicity assay, and RST
mitochondrial inhibitory/uncoupling assays from the no organ toxic drugs. For
nephrotoxic drugs, there was a statistically significant difference for hydrogen donor &
acceptor count, TPSA, MW, and Cmax values from the no organ toxic drugs. For
cardiotoxic drugs, there was a statistically significant difference for cLogP and THLE
cytotoxicity assay from the no organ toxic drugs.
The collinearity assessment found that the results of both HepG2 glucose and
HepG2 galactose in vitro assays were highly correlated (via variance inflation factors,
condition indices, and variance proportions).

These two variables are cell-based

assays measuring mitochondrial health as cell viability in two different media, glucose,
and galactose. HepG2 galactose assay along with the ratio of the cytotoxicity results
allow the detection of drugs causing mitochondrial toxicity in cell- based assays.31, 47 In
galactose media, HepG2 cells are forced to use mitochondrial oxidative
phosphorylation (circumventing the Crabtree effect) instead of glycolyis making them
more prone to drugs causing mitochondrial toxicity.31 Therefore, the results in the
HepG2 glucose assay were removed for further statistical modeling, while HepG2
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galactose assay, along with the ratio of the cytotoxicity results for mitochondrial health,
were used.
Univariate regression models for hepatotoxic, nephrotoxic, and cardiotoxic
drugs
The literature references and the cut-off criteria utilized for physicochemical
properties and in vitro assays for statistical analyses are shown in Table 1. The
univariate logistic regression models were specified after dichotomizing the individual
variables based on published criteria and their association with toxicities. Table 3
includes the odds ratios, confidence intervals, and p-values of the univariate logistic
regression models for hepatotoxic (A), nephrotoxic (B), and cardiotoxic drugs (C). In
the hepatotoxic model, p-values were less than 0.2 for Fsp3, Cmax, THLE cell viability
assay, glucose/galactose ratio, and RST mitochondrial inhibitory/uncoupling assays.
In the nephrotoxic model, p-values were less than 0.2 for physicochemical properties
such as hydrogen donor and acceptor count, clogP, TPSA, MW, Cmax, and RST
mitochondrial inhibitory assay. Similarly, for the cardiotoxic model, p-values were less
than 0.2 for hydrogen donor count, Cmax, THLE cell viability assay, HepG2
glucose/galactose cytotoxicity ratio, and RST mitochondrial inhibitory assays. The
variables that had p-values less than 0.2 in all three drug groups were further included
in the multivariable regression model.
Stepwise multivariable regression model (via backward elimination) for
hepatotoxic, nephrotoxic, and cardiotoxic drugs
A stepwise regression model via backward elimination was utilized to choose
the statistically significant predictive variables for each drug toxicity category. All the
descriptors with p-values less than 0.2 (Fsp3, Cmax, THLE cell viability assay,
glucose/galactose ratio, and RST mitochondrial inhibitory/uncoupling assays) were
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included to build a hepatotoxic multivariable model. In the multivariable hepatotoxic
predictive model, Cmax (odds ratio 7.5; 95% CI 3.16-17.79; p < 0.0001), and RST
mitochondrial inhibitory assay (odds ratio 6.21; 95% CI 1.69-22.79; p = 0.0059) were
significant predictors (Figure 1A).
Similarly, hydrogen donor and acceptor count, clogP, TPSA, MW, Cmax, and
RST mitochondrial inhibitory assay were included to build the nephrotoxic predictive
model. In the multivariable nephrotoxic model, hydrogen acceptor (odds ratio 15.94;
95% CI 2.85-89.00; p = 0.0016), TPSA (odds ratio 0.21; 95% CI 0.061-0.74; p = 0.01),
Cmax (odds ratio 5.86; 95% CI 2.03-16.9; p = 0.001), and RST mitochondrial inhibitory
assay (odds ratio 6.43; 95% CI 1.05-39.31; p = 0.043) were the significant predictors
(Figure 1B).
Finally, hydrogen donor count, Cmax, THLE cell viability assay, HepG2
glucose/galactose cytotoxicity ratio, and RST mitochondrial inhibitory assays were
included to build cardiotoxic predictive model.

In the multivariable cardiotoxic

predictive model, only the galactose assay (odds ratio 2.77; 95% CI 1.07-7.19; p =
0.036) indicated a statistically significant prediction of toxicity (Figure 1C).
Evaluation of predictive model performance via ROC-AUC (Receiving Operating
Curves – Area Under Curve) and the Hosmer and Lemeshow goodness-of-fit
tests
Assessment of the predictive models was conducted using ROC-AUC, as
shown in Figures 2 (A, B, and C). Figure 2A shows the ROC-AUC values of all the
predictors individually, along with the combinations of other statistically significant
predictors. For the hepatotoxic model, utilizing Cmax, RST mitochondrial inhibition,
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and THLE cytotoxicity assays, the AUC-ROC value was 0.78, indicating a good fit for
the predictive model.
Similarly, Figures 2B and 2C show the ROC-AUC values of all the predictors
individually along with a combination of other statistically significant predictors for
nephrotoxic and cardiotoxic models, respectively. As shown in Figure 2B, for the
nephrotoxic predictive model, based on hydrogen acceptor, TPSA, MW, Cmax, and
RST mitochondrial inhibition assay, the AUC-ROC value was 0.84, indicating a good
predictive model.

The cardiotoxic predictive model did not perform as well as

hepatotoxic and nephrotoxic models, having a ROC-AUC value of 0.65 (as shown in
Figure 2C). For the cardiotoxic predictive model, it can be assumed that this model
can predict the cardiotoxic drug only slightly better than a random classifier.
The Hosmer and Lemeshow goodness-of-fit tests were performed to determine
if the model for each drug toxicity group fit adequately. The three predictive models fit
appropriately (p = 0.43 for the hepatotoxic model, p = 0.84 for the nephrotoxic model,
and p = 0.21 for the cardiotoxic model).
Utilization of an ECCS to predict organ toxic drugs
Based on the ECCS, compounds are categorized as Class 1-metabolism as
mainly systemic clearance mechanism (high permeability acids/zwitterions with MW ≤
400 Da), Class 2-where metabolism is primary clearance mechanism (high
permeability

bases/neutrals),

Class

3A-renal

clearance

(low

permeability

acids/zwitterions with MW ≤ 400 Da), Class 3B-transporter mediated hepatic uptake or
renal clearance (low permeability acids/zwitterions with MW ≥ 400 Da), and Class 4renal clearance (low permeability bases/neutrals). The study reported that none of the
ECCS classes were associated with hepatotoxic or cardiotoxic drugs (as shown in
Tables 4, 5A, and 5C). However, ECCS class 2 (odds ratio 0.225; CI 0.095-0.535; p =
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0.0007) and ECCS class 4 (odds ratio 4.1; CI 1.77-9.52; p = 0.001) showed
discriminatory value for predictions of nephrotoxic drugs from the drugs with no organ
toxicity with lessor or greater odds ratios, respectively (as shown in Table 5B).
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1.5 DISCUSSION
Accurate prediction of safety-related severe adverse effects of drug candidates
early in the development process is a high priority for pharmaceutical companies.
There are various stages of drug development; for example, Exploratory Screen
Development (ESD), Screening Designed Synthesis (SDS), Lead Development (LD),
Candidate Selection (CS) leading to Candidate Alert Notice (CAN).

It is generally

believed that utilization of in vitro or in silico derived predictive models at the early
stages of discovery improves clinical toxicity prediction. Different pieces of information
are available at different stages of drug development.

For example, known or

calculated physicochemical properties information is available at the ESD or SDS
stage. In contrast, various in vitro assays (to assess general cytotoxicity, mitochondrial
dysfunction, or bile salt export pump disruption) are usually performed at the LD stage
where enough drug product is made for testing after other chemical properties have
been refined/optimized. At ESD or SDS stage, where hundreds or thousands of
compounds need to be screened, high throughput models described in this study are
utilized due to simplicity and low cost. In contrast, at lead development or compound
selection stage where a sufficient amount of material and few compounds are
nominated for further development, utilization of more expensive human primary or
more complex 3D spheroid or organ on a chip model (on the microfluidic platform) are
utilized when warranted. Furthermore, during preliminary exploratory toxicity studies
(at LD or CS stage) if there is evidence for particular organ toxicity, organ-specific
physiologically relevant predictive models are utilized to understand the in vivo animal
toxicity translation to human. Therefore, it is essential to understand the impact of
different in silico or in vitro assays predictors associated with different organ toxicities
in order to implement them at the correct stage of the drug development.
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The liver, kidney, and heart have been recognized as three major organ
systems that contribute to costly late-stage drug attrition.48 Therefore, there has been
an increased need to develop various predictive approaches that can identify drug
safety liabilities for these organs during the drug design and preclinical stages of the
drug development process. For example, various predictive models based on the
physicochemical properties of a drug or its effect on in vitro toxicity assays to predict
the human hepatotoxicity potential of a drug.14,
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These reported models have

limitations as they utilized either physicochemical properties or in vitro assays alone.
Furthermore, most of the models have been developed to predict only human clinical
hepatotoxicity.

Although more recent work has shown the value of integrating

physicochemical properties along with in vitro assays of relevance for predicting
hepatotoxicity,35 there is a significant gap in the literature for predictive models of
nephrotoxicity and cardiotoxicity based on combined approaches that integrate
physicochemical properties with in vitro assay results.
In this study, multivariable logistic regression models were developed for
predictions of hepatotoxicity, nephrotoxicity, and cardiotoxicity. The present study
used basic physicochemical properties (hydrogen bond donor & acceptor count, Fsp3,
cLogP, TPSA, MW, and Cmax values), and the in vitro toxicity assay results (THLE
cytotoxicity

assay,

glucose/galactose

assays,

and

RST

mitochondrial

inhibitory/uncoupling assays) for 215 pharmaceutical drugs. These assays represent
large-scale screening assays in use either generally or on an ‘ad hoc’ basis at the drug
design and preclinical stages of the drug development process.
Hepatotoxicity
Our study concluded that, based on the hepatotoxic predictive model, if a drug
were to be positive in THLE cell viability assay (IC50 values less than 100 µM) or caused
mitochondrial toxicity via mitochondrial inhibition (IC50 values less than 100 nmoles/mg
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of protein) or had clinical Cmax value of greater than 1 µM, it was 2, 6.2 or 7.5 times
more likely to cause liver injury respectively. Combining these separate descriptors in
a single hepatotoxicity model had a ROC-AUC value of 0.78, suggesting that these
three descriptors were most influential in separating hepatotoxic drugs from drugs with
no known organ toxicity. For hepatotoxicity predictions, using this dataset, cytotoxicity,
mitochondrial inhibition, and clinical Cmax were stronger predictors than the other
physicochemical properties analyzed. Systemic exposure, as measured by Cmax, and
followed by evidence of mitochondrial inhibition, were influential descriptors, but are
known or testable at different times during the drug development process compared to
physicochemical properties. Although cLogP and TPSA values have been used for
general toxicity prediction by Hughes et al., they provided a poorer model fit with an
AUC-ROC value of only 0.576 (as shown in figure 2A).10 Leeson reported that low Fsp3
values needed to be combined with high lipophilicity and applied dose values to be
useful for predicting “Most DILI’ drugs.14 However, as an individual descriptor, Fsp3
provided a poorer model fit for this dataset with an AUC-ROC value of only 0.573 (as
shown in figure 2A) and did not add as much additional value as the combination of
Cmax, THLE cytotoxicity, and mitochondrial inhibitor descriptors. Differences between
these two models may be driven by differences in the analysis approach as optimized
physicochemical cut-off values for applied dose, cLogP, and Fsp3 values were
developed and used by Leeson for individual ionization states based on an extremely
larger dataset compared to our study.14
We also investigated the use of our in-house ECCS classification system for
hepatotoxicity prediction. To our knowledge, this is the first study that attempted to
use the ECCS class for the prediction of hepatotoxicity. However, unlike BDDCS
classification, ECCS classification, based on our dataset, were not able to add value
to predict hepatotoxic drugs.15-17 As stated earlier, ECCS primarily predicts the rate-
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determining clearance mechanism, while BDDCS predicts the extent of elimination
and solubility. Although BDDCS classification appears more useful for understanding
and categorizing different clearance mechanisms for predictions of hepatotoxicity,15-17
it may not be practical in drug design and selection to avoid the development of
BDDCS class 2 drugs, as previously suggested.19 Many drugs in this category offer
the intended therapeutic benefit with a low incidence of clinical hepatotoxicity issues
due to low (≤100 mg) applied dose (e.g., montelukast, losartan, telmisartan, nifedipine,
simvastatin, and pioglitazone).
Nephrotoxicity
Based on the nephrotoxicity predictive model, it was concluded that if a drug
had a clinical Cmax greater than 1 µM or inhibits mitochondrial respiration at IC50 less
than 100 nmoles/mg of protein, or has hydrogen bond acceptor atoms greater than 7,
it is 5.8, 6.4 or 15.9, times more likely to cause kidney injury, respectively. Conversely,
drugs that had a TPSA ≥75 Å2 and a MW<400 Da, were 79% and 71% less likely to
cause kidney injury, respectively. The nephrotoxic model had a ROC-AUC value of
0.844, indicating that the descriptors were able to separate nephrotoxic drugs from the
no organ toxic drugs. Consequently, for the nephrotoxicity prediction, physicochemical
properties had much higher significance based on odds ratios that were either highly
correlated with increased (hydrogen bond acceptor ≥ 7) or decreased (TPSA > 75 Å2
and a MW < 400 Da) correlation to nephrotoxicity compared with clinical Cmax and
mitochondrial inhibition assays. This finding is consistent with literature that correlates
highly toxic compounds with more hydrogen bond acceptor atoms.49-51 It is suggested
that the compounds with more hydrogen bond acceptor atoms are highly reactive.49
Drugs with high hydrogen bond acceptor atom may be more reactive at low
concentrations

through

macromolecules.49

interactions

with

enzymes

or

cellular

receptor

To our knowledge, there are no studies that associated high
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hydrogen bond acceptor atom with nephrotoxicity. This study found that this
physicochemical property exceeded clinical Cmax exposure as a predictor in terms of
the magnitude of its odds ratio.

There have been previous publications that

demonstrate the association of MW(≥ 400 Da), TPSA (< 75Å2), and Cmax (> 1 µM)
with toxic drugs.10, 13, 39, 49, 52 Based on our dataset, the TPSA combined with higher
Cmax values showed the importance of predicting kidney injury. Out of all the in vitro
assays used here, only RST mitochondrial inhibition assay showed the importance of
predicting kidney injury. However, in our opinion, assessing other in vitro approaches
may be necessary to better stratify nephrotoxicity risks, given that our first-tier
cytotoxicity assays are based on liver-derived cell lines (THLE and HepG2). For better
predictions of nephrotoxicity, it may be more important to use primary cultures of renal
cells or 3 dimensional (3D) organoids that would have a correct balance of renal uptake
and secretion transporters.53

Lin et al. reported that organ-specific toxicity (liver,

kidney, and heart) was not better predicted using the corresponding organ-derived
immortalized cell lines.30 Factors such as drug accumulation within specific organ cell
types, off-target effects, organ-specific drug metabolism, and clearance may need to
be assessed since these factors have a significant impact on specific organ toxicity.30
Interestingly, our study concluded that if a drug is in ECCS class 4, where
metabolism is primarily through renal clearance (low permeability bases and neutrals),
it was four times more likely to cause kidney injury than other ECCS class drugs. On
the other hand, ECCS class 2 drugs were 77% less likely to cause kidney injury.
Hepatic metabolism is the primary clearance mechanism of ECCS class 2 drugs (high
permeability bases and neutrals). Class 4 drugs are more likely to be distributed and
accumulate within the kidney, making them more likely to damage proximal tubule
kidney cells. Again, due to their primary route of clearance, either kidney or liver,
different classes of drugs tend to accumulate in different organs leading to different
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organ damage.

Our study was successfully able to utilize the ECCS class for

differentiating nephrotoxic drugs from drugs with no known organ toxicity.
Cardiotoxicity
Based on the univariate cardiotoxicity predictive model, it was concluded that if
a drug is positive in galactose assay (IC50 values less than 100 µM) and has clinical
Cmax values greater than 1 µM, it was 2.7 and 1.8 times more likely to cause
cardiotoxicity, respectively. Similarly, if a drug has hydrogen bond donor atoms less
than 5, it was 72% less likely to cause heart injury. The cardiotoxic model had a ROCAUC value of 0.65, indicating a less robust model fit compared to the hepatotoxicity
and nephrotoxicity models, and the cardiotoxic predictive model was less able to
separate the cardiotoxic drugs from the no organ toxic drugs. Heart organ injury has
both functional (conduction) and structural components. The compounds selected for
our analysis were a mixture of structural and functional cardiotoxicants. Clement et al.
reported the more holistic approach of integrating electrophysiology, contractility, and
cell movement/beating for functional assessment along with various structural
assessments for cardiotoxicity.54 This holistic approach may hold increased value for
predicting cardiotoxic drugs as they are based on more relevant functional parameters
of cell health and function.
Important pieces of information become available at different times during the
drug discovery, design, and development process.

Known or calculated

physicochemical properties are determined at the drug design stage such that these
descriptors can be utilized in predictive models of safety. Likewise, drug effects in
mechanistic in vitro assays can only be determined when drug product is made. While
estimates of applied dose and clinical exposure are made close to candidate
nomination, these values are validated during Phase 2 clinical studies.

It was

important for us to determine which descriptors could be used based on the predictive
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odds ratio for each organ model and consider when such information would be
available. Predictions of hepatotoxicity required information that was available after
compound design, making a predictive model hard to implement in that space. Most
predictive hepatotoxicity models require the use of clinical dose or systemic exposure
(Cmax) with physicochemical property space predictors to be useful. In advance of
this, measurements of mitochondrial inhibition appear to add some value.

Both

mitochondrial inhibition of oxidative phosphorylation and drug plasma concentration
(Cmax) were two descriptors that were useful in predicting both liver and kidney toxicity.
This finding agreed with previous studies by Porceddu et al., who used multiparametric
mechanistic endpoints of mitochondrial dysfunction combined with drug plasma
concentration to predict DILI with high sensitivity and high positive predictive values.24
Of even more significance is the finding that physicochemical properties could be used
for predictions of nephrotoxicity, with either highly correlative positive (hydrogen bond
acceptors ≥7, ECCS class 4) or negative (TPSA ≥75 Å2, MW<400 Da, ECCS class 2)
predictions. Such descriptive elements could be used in the drug design process for
compound design and selection, although ECCS class determinations still require drug
bulk for passive membrane permeability. None of the drug attributes appeared to help
define the cardiotoxic risks of drugs.
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1.6 LIMITATION
This data set utilized drugs where in vitro data results are available, which leads
to a relatively small number of drugs evaluated in this study. Additionally, this may
introduce selection bias since the drugs used in this study may not be random.

A

small sample size may lead to a large confidence interval in the calculation of the odds
ratio, and the lack of statistical power may result a type II error. The whole dataset
was used to build models, therefore further studies utilizing these models with
additional data will be required. Furthermore, due to the small number of drugs utilized
to build predictive models, the findings may not be generalized to all the drugs. The
result of this study should only be applied to the physicochemical properties of the
drugs evaluated here; the drugs that fall outside of the physicochemical property space
evaluated here may hold different results. Finally, the result of this study will not be
relevant to biotherapeutic drugs.
To employ logistic regression modeling, drugs were only classified as having
one type of toxicity; many drugs in the dataset have been associated with multiple
organ toxicities. Additionally, increased risk or association does not imply causation.
Further study is necessary to evaluate the predictive nature of these factors using more
robust methodologies or in vitro/in vivo mechanistic toxicity studies. Finally, other
factors beyond physicochemical properties or in vitro assays can cause toxicity in vivo.
For instance, in vitro assays lack metabolic functions, appropriate receptors and
transporters, and cellular architecture. Moreover, drug-accumulation within specific
organ cell types, off-target effects, organ-specific drug metabolism, and clearance may
lead to organ toxicity. Measuring these factors was beyond the scope of this study;
however, their inclusion would likely have enhanced the models.
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1.7 CONCLUSION
The physicochemical properties of a drug influence various parameters such as
absorption, clearance, the volume of distribution, total plasma concentration, and
dosing frequency. Measurements of passive membrane permeability along with RST
mitochondrial inhibition are useful and relatively affordable compared with in vivo
animal toxicity studies. Therefore, we recommend a blended approach of utilizing
readily calculated physicochemical properties combined with in vitro toxicity
assessments to select molecules with less potential for clinical organ toxicity for the
liver and kidney.

As suspected, different models are needed for more accurate

predictions of hepatic and nephrotoxic drugs. The multivariable analysis showed that
drug plasma concentration combined with mitochondrial dysfunction assays was most
useful in the prediction of hepatotoxic drugs. However, for nephrotoxic drugs, the
physicochemical properties of the drugs such as TPSA and hydrogen acceptor atoms
combined with drug plasma concentration, and mitochondrial dysfunction assay were
most useful. Mitochondrial dysfunction assay and drug plasma concentration are two
descriptors that were useful for predicting organ toxicity for both liver and kidney.
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1.9 TABLES AND FIGURES
Table 1. Literature references and the threshold utilized for the
physicochemical properties and the in vitro assays for univariate and
multivariable logistic regression modeling.

Physicochemical properties and in vitro assay thresholds
utilized for univariate and multivariable logistic regression
modeling

Literature
reference

Toxic (1)

Not Toxic (0)

Hydrogen bond donor atoms
≥5
Hydrogen bond acceptor
atoms ≥ 7

Hydrogen bond donor atoms < 5

39

Hydrogen bond acceptor atoms
<7

39

Fsp3 ≤ 0.28

Fsp3 > 0.28

14

cLogP ≥ 3
TPSA < 75 Å2

cLogP < 3
TPSA ≥ 75 Å2

10, 12, 13, 27, 52

MW ≥ 400 Da

MW < 400 Da

14, 39

Cmax > 1 µM

Cmax ≤ 1 µM

10, 12, 14, 41, 55

THLE assay IC50 ≤ 100 µM

THLE assay IC50 > 100 µM

13, 27

Glucose assay IC50 ≤100 µM

Glucose assay IC50 > 100 µM

13, 27

Galactose assay IC50 ≤100
µM
Glucose/galactose ratio ≥ 2
RST Uncoupling assay IC50
≤ 100 nmol/mg of protein
RST Inhibitory assay IC50 ≤
100
nmol/mg of protein

Galactose assay IC50 > 100 µM

13, 27

Glucose/galactose ratio < 2
RST Uncoupling assay IC50 >
100 nmol/mg of protein
RST Inhibitory assay IC50 > 100
nmol/mg of protein

27

33

10, 12, 13, 27, 52

27

27

Table 2. Characteristics of physicochemical properties and in vitro assay
results of organ toxicity drugs.
Hepatotoxic
(N=70)

Nephrotoxic
(N=45)

Cardiotoxic
(N=44)

No Organ toxic
(N=56)

Independent
Predictors
Hydrogen
donor count
Hydrogen
acceptor count

1.942 ± 0.20

5.844 ±
0.864*

1.84 ± 0.22

2.785 ± 0.458

3.957 ± 0.31

8.02 ± 0.85*

3.63 ± 0.45

3.96 ± 0.45

Fsp3

0.364 ±
0.031

0.423 ± 0.047

ClogP

2.688± 0.303

0.90 ± 0.71

Cmax
THLE cell
viability assay

80.043 ±
5.17
351.6 ±
16.74
13.43 ± 2.83*
181.9 ±
14.14*

166.6 ±
18.34*
508.5 ±
47.57*
13.76 ± 3.34*

Glucose Assay

237.2 ± 5.44

256.0 ± 12.78

Galactose
Assay
RST Inhibitory
Assay
RST
Uncoupler
Assay

216.5 ±
12.81

237.6 ± 14.67

223.6 ± 13.8*

264.4 ± 11.52

216.9 ±
14.91*

266.5 ± 11.82

TPSA
MW

Mean ± SEM

221.6 ± 16.32

*p < 0.05
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0.387 ±
0.0246
3.81 ±
0.238*
65.12 ± 6.49
347.7
±17.54
5.14 ± 1.85
169.9 ±
17.63*
209.9±
17.37
193.2 ±
18.52
263.3 ±
13.11
244.5 ±
14.88

0.40 ± 0.03
1.72 ± 0.423
84.72 ± 11.43
340.8 ± 23.93
7.20 ± 2.54
230.2 ± 13.83
232.0± 13.85
229.0 ± 16.04
282.7 ± 8.45
257.8 ± 11.58

Table 3A. Odds of hepatotoxic risk associated with physicochemical properties
and in vitro assays.

Univariate Logistic Regression Model
Hepatotoxic Drugs

Physicochemical
Properties

Independent
Variables
Hydrogen donor
count
Hydrogen acceptor
count
Fsp3

Odds
Ratio

95% CI

p-value

0.58

0.202-1.671

0.3131

0.926

0.293-2.929

0.8955

1.933

0.905-4.129

0.0887*

cLogP

1.24

0.613-2.51

0.5498

TPSA

0.658

0.324-1.338

0.2479

MW

1.516

0.681-3.373

0.3078

Cmax
5.455
2.529-11.76
<0.0001*
THLE cell viability
2.302
1.035-5.120
0.0409*
assay
Galactose assay
1.363
0.564-3.294
0.4916
Glucose/galactose
In vitro assays
6.111
0.729-51.233
0.0952*
ratio
RST inhibitory assay
5.957
1.914-18.536
0.0021*
RST uncoupling
1.875
0.817-4.301
0.1378*
assay
*All the variables where p-values are less than 0.2 were included to build the
multivariable model
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Table 3B. Odds of nephrotoxic risk associated with physicochemical
properties and in vitro assays.

Univariate Logistic Regression Model
Nephrotoxic Drugs

Physicochemical
Properties

Independent
Variables
Hydrogen donor
count
Hydrogen acceptor
count
Fsp3

Odds
Ratio

95% CI

p-value

4.177

1.658-10.526

0.0024*

8.712

3.114-24.377

<0.0001*

1.66

0.713-3.861

0.2397

cLogP

0.56

0.246-1.274

0.167*

TPSA

0.174

0.071-0.430

0.0002*

MW

3.78

1.611-8.871

0.0023*

Cmax
4.118
1.784-9.502
0.0009*
THLE cell viability
0.917
0.348-2.419
0.861
assay
Galactose assay
0.708
0.236-2.123
0.5373
Glucose/galactose
In vitro assays
3.929
0.394-39.127
0.243
ratio
RST inhibitory assay
2.811
0.788-10.029
0.1113*
RST uncoupling
0.754
0.266-2.135
0.5944
assay
*All the variables where p-values are less than 0.2 were included to build the
multivariable model
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Table 3C. Odds of cardiotoxic risk associated with physicochemical properties
and in vitro assays.

Univariate Logistic Regression Model
Cardiotoxic Drugs
Independent
Odds
95% CI
p-value
Predictors
Ratio
Hydrogen donor
0.249
0.051-1.217
0.0858*
count
Hydrogen acceptor
0.397
0.0076-2.071
0.2728
count
Physicochemical
Fsp3
0.607
0.231-1.599
0.3127
Properties
ClogP
1.488
0.673-3.29
0.3263
TPSA
1.494
0.652-3.419
0.3425
MW
1.387
0.566-3.401
0.4745
Cmax
1.731
0.751-3.989
0.1979*
THLE cell viability
1.897
0.777-4.628
0.1597*
assay
Galactose assay
2.629
1.048-6.591
0.0393*
Glucose/galactose
7.05
0.792-62.733
0.0799*
In vitro assays
ratio
RST inhibitory
2.459
0.671-9.014
0.1744*
assay
RST uncoupling
1.364
0.528-3.522
0.5217
assay
*All the predictors where p-values are less than 0.2 were included to build the
multivariate model
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Table 4. Comparison of hepatotoxic, cardiotoxic, and nephrotoxic drugs with
the Extended Clearance Classification System.

Extended Clearance
Classification System Properties

Organ toxicity drugs

ECCS
Class

Metabolism
Clearance

Hepatotoxic
(p-value)

Nephrotoxic
(p-value)

Cardiotoxic
(p-value)

Class 1A

Systemic
Clearance

NS

NS

NS

Class 1B

Systemic
Clearance
(Transporter
mediated uptake)

NS

NS

NS

Class 2

Metabolism
clearance

NS

0.0007

NS

Class3A

Renal clearance

NS

NS

NS

NS

NS

NS

NS

0.001

NS

Class3B
Class4

Transporter
mediated hepatic
uptake or renal
clearance
Renal clearance

NS - Not Significant; p > 0.05
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Table 5 Univariate logistic regression model (including odds ratio estimates,
95% CI, and p-values) for hepatotoxic, nephrotoxic, and cardiotoxic drugs
using the Extended Clearance Classification System.

Hepatotoxic drugs
ECCS Class

Odds Ratio

95% CI

p-value

Class 1

2.46

0.25-24.35

0.44

Class 2

0.93

0.46-1.90

0.84

Class3A

>999.9

<0.001->999.9

0.98

Class3B

>999.9

<0.001->999.9

0.99

Class 4

0.93

0.45-1.92

0.83

Nephrotoxic drugs
ECCS Class

Odds Ratio

95% CI

p-value

Class 1

<0.001

<0.001->999.9

0.98

Class 2

0.225

0.095-0.535

0.0007

Class3A

>999.9

<0.001->999.9

0.98

Class3B

<0.001

<0.001->999.9

0.99

Class 4

4.1

1.77-9.52

0.001

Cardiotoxic drugs
ECCS Class

Odds Ratio

95% CI

p-value

Class 1

<0.001

<0.001->999.9

0.99

Class 2

1.66

0.72-3.84

0.23

Class3A

NA*

NA*

NA*

Class3B

<0.001

<0.001->999.9

0.99

0.3-1.63

0.41

Class 4
0.70
*NA- Not applicable
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Figure 1A: Adjusted odds ratio (including 95% Confidence Interval (CI)) of
hepatotoxic risk associated with physicochemical properties and in vitro
assays
Multivariable logistic regression model for hepatotoxicity
prediction

THLE assay

1.99

(CI-0.73-5.46; p = 0.18)

RST inhibitory assay

6.21 (CI-1.69-22.8; p = 0.059)

Cmax

7.5 (CI-3.16-17.8; p < 0.0001)

Adjusted odds ratio
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Figure 1B: Adjusted odds ratio (including 95% CI) of nephrotoxic risk
associated with physicochemical properties and in vitro

Multivariate logistic regression model for nephrotoxicity
prediction

MW

0.29 (CI-0.05-1.54; p-value-0.15)

TPSA

0.21 (CI-0.06-0.74; p-value-0.0153)

Cmax

5.86
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(CI-2.03-16.9; p-value-0.001)
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Adjusted odds ratio
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Figure 1C: Adjusted odds ratio (including 95% CI) of cardiotoxic risk associated
with physicochemical properties and in vitro assays

Multivariable logistic regression model for cardiotoxicity
prediction
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Figure 2A: Hepatotoxic model performance evaluation via ROC-AUC, a plot of
sensitivity Vs. 1-specificity.
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Figure 2B: Nephrotoxic model performance evaluation via ROC-AUC, a plot of
sensitivity Vs. 1-specificity.
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Figure 2C: Cardiotoxic model performance evaluation via ROC-AUC, a plot of
sensitivity Vs. 1-specificity.

45

MANUSCRIPT II

Title: Hepatotoxicity reports in the FDA adverse event reporting
database: a comparison of drugs that cause injury via mitochondrial or
other mechanisms
Payal Rana*a, b, Michael D. Aleo, Xuerong Wenb, Fatemeh Akhlaghi b and
Stephen Kogutb
a

Drug Safety Research & Development, Pfizer, Eastern Point Road, Groton, CT

06340, USA
b

University of Rhode Island, College of Pharmacy, Kingston, RI 02881, USA

*Corresponding author: Address: Payal Rana, Drug Safety R&D, Eastern Point Road,
Groton, CT 06340, USA; email: payal.m.rana@pfizer.com
Funding: Unfunded
Journal: Formatted for submission to Drug Safety
Publication Status: The manuscript is in final stages of submission

46

2.1 ABSTRACT
Drug-induced liver injury (DILI) is a leading reason for preclinical safety attrition and
post-market drug withdrawals. Drug-induced mitochondrial toxicity has been shown
to play an essential role in various forms of DILI, especially in idiosyncratic liver injury.
This study examined liver injury reports submitted to the Food and Drug Administration
(FDA) Adverse Event Reporting System (FAERS) for drugs associated with
hepatotoxicity via mitochondrial mechanisms compared with non-mitochondrial
mechanisms of toxicity. The frequency of hepatotoxicity was determined at a group
level and individual drug level. A Reporting Odds Ratio (ROR) was calculated as the
measure of effect. Between the two DILI groups, reports for DILI involving
mitochondrial mechanisms of toxicity had a 1.43 (95% CI 1.42-1.45; p < 0.0001) times
higher odds compared to drugs associated with non-mitochondrial mechanisms of
toxicity. Antineoplastic, antiviral, analgesic, antibiotic, and antimycobacterial drugs
were the top 5 drug classes with the highest ROR values. Although the top 20 drugs
with the highest ROR values included drugs with both mitochondrial and nonmitochondrial injury mechanisms, the top 4 drugs (ROR values >18: benzbromarone,
troglitazone, isoniazid, rifampin) were associated with mitochondrial mechanisms of
toxicity. The major demographic influence for DILI risk was also examined. There was
a higher mean patient age among reports for drugs that were associated with
mitochondrial mechanisms of toxicity (56.1 ± 18.33 (SD)) compared to nonmitochondrial mechanisms (48 ± 19.53 (SD)) (p < 0.0001), suggesting that age may
play a role in susceptibility to DILI via mitochondrial mechanisms of toxicity. Univariate
logistic regression analysis showed that reports of liver injury were 2.2 (odds ratio: 2.2,
95% CI 2.12-2.26) times more likely to be associated with older patient age, as
compared with reports involving patients less than 65 years of age. Compared to
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males, female patients were 37% less likely (odds ratio: 0.63, 95% CI 0.61-0.64) to be
subjects of liver injury reports for drugs associated with mitochondrial toxicity
mechanisms. Given the higher proportion of severe liver injury reports among drugs
associated with mitochondrial mechanisms of toxicity, it is essential to understand if a
drug causes mitochondrial toxicity during preclinical drug development when drug
design alternatives, more clinically relevant animal models, and better clinical
biomarkers may provide a better translation of drug-induced mitochondrial toxicity risk
assessment from animals to humans.

Our findings from this study align with

mitochondrial mechanisms of toxicity being an important cause of DILI, and this should
be further investigated in real-world studies with robust designs.
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2.2 INTRODUCTION
Severe drug-induced liver injury (DILI) is a rare, potentially life-threatening
adverse event with an incidence of 10-15 cases per 10,000 to 100,000 patients per
year.1-4 The clinical profile of DILI is challenging to diagnose as it can mimic almost any
type of liver disease

5, 6

and mild, asymptomatic transaminase elevations may mimic

those caused by diet.7

Prediction of liver injury remains a challenge for the

pharmaceutical industry, regulators, and clinicians.5 DILI symptoms range from nonspecific mild elevations in liver enzymes (aminotransferases) to severe liver illnesses
such as cirrhosis or acute hepatitis5, 6 and there is no specific biomarker that links drug
exposure as the contributing cause of liver injury.8
There are two types of DILI: intrinsic (i.e., dose-dependent) and idiosyncratic
(i.e., dose-independent).6 A well-known example of intrinsic DILI is acetaminopheninduced liver injury, as it is dose-dependent, the onset is hours to days, and
predictable.9 On the other hand, idiosyncratic DILI is not dose-dependent, occurs in a
small portion of drug-exposed individuals, its onset is days to weeks, and
unpredictable.9 Idiosyncratic DILI is highly dependent on environmental and host
factors that alter the susceptibility of individual patient responses to the drug. Hamilton
et al. suggested that DILI is the convergence of three influencing risk factors: host
factors, environmental factors, and drug-specific factors.10 Host-related risk factors
include genetics, ethnicity, gender, comorbidities, alterations in drug transport, drug
clearance capabilities, age, and mitochondrial function variability.10 Environmental risk
factors include lifestyle, viral co-infection, co-prescriptions, diet, and alcohol
consumption.10 Finally, drug-specific risk factors include the relationship of applied
dose (exposure) and chemical structure with reactive metabolite formation,
mitochondrial dysfunction, and lipophilicity.10-12 Therefore, the mechanism of DILI is a
highly complex process that varies from patient to patient and is influenced by host,
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environmental, and drug-specific factors that influence the liver’s ability to adapt and
recover from an injury caused by a drug.8
In recent years, drug-induced mitochondrial toxicity has been shown to play an
essential role in intrinsic and idiosyncratic DILI. Many medications from different drug
classes, such as antidiabetic, antilipidemic, antiviral, antibiotic, anti-inflammatory, and
antipsychotic agents have toxicities mediated by mitochondrial mechanisms, which
may contribute to DILI.13 Mitochondrial toxicants affect mitochondrial homeostasis by
numerous mechanisms such as oxidative stress, inhibition or uncoupling of respiratory
complexes of electron transport chain, impairment of mitochondrial replication or
promoting mitochondrial DNA damage.14 Drug-induced mitochondrial toxicity is difficult
to be detected in standard preclinical animal testing models and requires specific
studies to examine disruptions in liver energy status.15 Only recently, there has been
the development of clinical biomarkers specific for mitochondrial dysfunction in
disease16 and DILI17 beyond changes in blood lactate. With these inadequacies, a
drug candidate can enter human clinical trials only to fail for evidence of mitochondrial
toxicity.18, 19 Examples of non-mitochondrial toxicity mechanisms that drive DILI are a
generation of reactive metabolites, activation of cell death pathways, activation of
innate or adaptive immune response pathways, or disruption of cellular homeostasis.20
This study evaluates the frequency of reports of hepatotoxicity injury in drugs that cause
DILI in mitochondrial mechanisms compared to the non-mitochondrial mechanisms.
Patient demographics influence risk or susceptibility for DILI. Boelsterli and Lim
(2007) indicated that older age and female gender were important susceptibility factors
for DILI; however, the reasons were still unknown.21 There are no clinical studies that
link the sensitivity of the female gender to DILI caused by mitochondrial dysfunction.
Amacher et al. indicated that women are more susceptible to DILI than men.22 Several
hypotheses were proposed to explain gender differences in susceptibility, including
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pharmacokinetic or pharmacodynamic differences, interactions of sex hormones with
signaling molecules, and a difference in immune system responses.22 Similarly, it is
believed that older adults are more susceptible to DILI caused by mitochondrial
dysfunction. The review published by Will et al.13 indicated that the most commonly
used prescription and over-the-counter (OTC) medications for geriatric patients, such
as antilipidemic, pain, and heartburn medications, had published reports of toxicities
linked to mitochondrial dysfunction.13

As the United States’ elderly population is

growing rapidly, identifying and addressing risk factors of DILI, where mitochondrial
dysfunction may play a substantial role in adverse events, will be beneficial to this
vulnerable patient population. Therefore, in this study, we evaluated the patient age
and gender associated with DILI reports (measured by reporting odds ratio) for
hepatotoxicants with mitochondrial and non-mitochondrial injury mechanisms.
Given that mitochondrial dysfunction is a common characteristic of drugs that
cause liver injury, a better understanding of the association between the probability of
liver injury induced by drugs that are mitochondrial toxicants and the influence of
patient's age and gender would be beneficial for clinicians and drug developers. If a
drug is associated with mitochondrial mechanisms of liver injury, clinicians could
incorporate mitochondrial injury-specific biomarkers into clinical trials.23-25 Additionally,
the development of clinically relevant animal models or study designs may provide
drug-induced mitochondrial toxicity risk translation from animals to humans.24
This study investigated liver injury reports submitted to the Food and Drug
Administration (FDA) Adverse Event Reporting System (FAERS) and compared the
frequency of reports between drugs that can cause hepatotoxicity via mitochondrial
mechanisms and those without mitochondrial mechanisms of toxicity. Additionally, we
determined if there were age and gender differences associated with DILI reports
involving drugs with or without mitochondrial toxicities.
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2.3 METHODS
Study design:
Data Source:
The United States Food and Drug Administration (FDA) Adverse Event
Reporting System (FAERS) database is the largest national repository of spontaneous
drug event reports, having accumulated over 28 million adverse events reports.
Healthcare professionals, patients, manufacturers, and lawyers can submit potential
drug-induced adverse events of small and large therapeutic (biologics) classes and
medical devices to the FAERS database. The FAERS database has a vital role in postmarket drug surveillance in terms of detection and characterization of drug and devicerelated adverse events.
We extracted adverse event reports from the FAERS database for the
timeframe from January 1998 to May 2019. In this study, the reports included severe
adverse events, such as hospitalization, disability, or death. The types of reports were
classified by FAERS as direct, expedited, or periodic. Direct reports were submitted
to FDA from consumer or health care professionals; whereas, expedited reports were
sent from the manufacturer within 15 days of severe adverse events occurrence not
included in the product label.26 Adverse drug event reports considered periodic were
submitted from manufacturers, included in the label, and sent to the FDA quarterly or
annually.26 The main selection criterion was “primary suspect” drugs. “Secondary
suspect” drugs were excluded because of the greater uncertainty of the association
between the drug and the reported adverse events. FAERS reports were coded using
the MedDRA (Medical Dictionary for Regulatory Activities) terms for DILI.27 Although
DILI has complex clinical symptoms, there has been documentation for the utilization
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of the FAERS database to investigate emerging DILI adverse events for newly
marketed drugs.8
Inclusion/exclusion criteria:
Drugs that cause liver injury have been annotated using the United States
National Center for Toxicological Research Liver Toxicity Knowledge Base (NCTRLTKB), which utilizes hepatotoxic descriptions from the FDA-approved drug labeling
regulatory documents as well as evaluating causality evidence in the literature.28 This
database was created by the FDA to help clinicians, toxicologists, and researchers
access information on DILI annotation of various drugs. 28, 29 NCTR-LTKB serves as a
centralized source to study the mechanism of DILI and the development or validation
of emerging biomarkers and predictive models.29 This is the largest publicly available
annotated DILI dataset containing three groups based on their potential to cause liver
toxicity (Most DILI concern-(192 drugs), Lesser DILI concern-(278 drugs), and No-DILI
concern (312 drugs)) with confirmed causal evidence connecting a drug to liver
injury.28

The FAERS database uses FDA drug labeling information for the

classification of drugs according to their potential to cause DILI. This study utilized
drugs with "most-DILI concern," which were defined based on hepatotoxicity resulting
in market withdrawal (in US and ex-US), black box warning, or high severity of liver
injury noted as part of the warning and precautions label.28-30

Therefore, both

mitochondrial and non-mitochondrial mechanisms of toxicity groups are associated
with severe hepatic injury.
The study drugs represented various drug classes such as analgesic, antiinflammatory, antidepressant, antibiotic, antidiabetic, and antineoplastic agents. Most
of these drugs had been withdrawn, have boxed warnings, or have warnings and
precautions for liver injury in their prescribing labels. The details of DILI severity
categories based on the DILI description are included in the drug labeling: severity
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level 1; steatosis, level 2; cholestasis and steatohepatitis, level 3; liver
aminotransferases increase, level 4; hyperbilirubinemia, level 5; jaundice, level 6; liver
necrosis, level 7; acute liver failure, and level 8; hepatotoxicity.28

Examples of

withdrawn drugs include bromfenac, chlorzoxazone, troglitazone, and trovafloxacin,
which have been assigned a severity level of 8, suggesting evidence of fatal
hepatotoxicity.

Drugs such as bosentan, danazol, ketoconazole, nefazodone,

tolcapone, and valproic acid have box warning in their product labeling and have
severity categories ranging from 3 to 8.
Classification of Drugs as Mitochondrial Toxicants:
Drugs with mitochondrial mechanisms of toxicity were defined by literature
evidence of mitochondrial injury mechanisms (yes or no) of in vitro (e.g., cellular
production of reactive oxygen species via oxidative stress, inhibition or uncoupling of
respiratory complexes of electron transport chain, induction of mitochondrial
membrane permeability transition pore, or mitochondrial DNA damage) or in vivo
mitochondrial toxicity from animal studies. Our classification was based on the parent
drug-induced toxicity and not the metabolite. Possible drug effects on mitochondrial
biogenesis or respiratory capacity were not considered. Drugs with the nonmitochondrial mechanisms of toxicity were defined by literature evidence of the
absence of mitochondrial injury mechanisms or lack of evidence. It is important to note
that 8.2% of drugs had no literature evidence of the type of toxicity mechanism,
meaning it could be a mitochondrial or non-mitochondrial mechanism. Furthermore,
the non-mitochondrial mechanisms of toxicity drugs are not proven to have nonmitochondrial mechanisms.

For these drugs, there is simply no evidence of

mitochondrial mechanisms of toxicity information that is publicly available yet.
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Outcome:
We determined the number of reports for hepatotoxicity at a group level and
an individual drug level using the Reporting Odds Ratio (ROR). As shown in Table 1,
we calculated total hepatotoxicity and all other adverse events for both the DILI groups.
For ROR calculations, numerators are derived by multiplying the hepatotoxicity reports
for mitochondrial mechanisms of toxicity drug group with all other adverse event
reports of non-mitochondrial mechanisms of toxicity per drug group. The denominator
is calculated by multiplying hepatotoxicity adverse event reports of non-mitochondrial
mechanisms of toxicity with all the adverse events reported for mitochondrial
mechanisms of toxicity per drug group.31 Therefore, the ROR for drugs associated
with mitochondrial mechanism of toxicity was 1.43 (ROR = (40,343 X 1,342,486) /
(586,989 X 64,358) = 1.43).
We also examined the RORs at the individual drug level, as shown in Table 2.
A case (hepatotoxicity reports) or non-case (all other adverse event reports)
disproportionality approach was utilized by creating a two-by-two contingency table,
as demonstrated below using acetaminophen as an example 31 During this timeframe,
a total of 383,540 hepatotoxicity reports and a total of 27,852,908 adverse event
counts of any drug type were collected. For ROR calculations, numerators are derived
by multiplying the hepatotoxicity reports for a drug of interest with all other adverse
events reports. The denominator is calculated by multiplying hepatotoxicity adverse
event reports of all other drugs (excluding acetaminophen) with all the adverse events
reported with a drug of interest31 (ROR for Acetaminophen = (8,509 X 27,852,908) /
(51,732 X 383,540) = 11.94). Within the timeframe, a ROR higher than 1 for a drug
indicates a higher proportion of severe liver injury reports for a drug of interest than all
the other drug reports in the database. In this case, acetaminophen was associated
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with proportionally more reports for serious liver adverse events than other drugs in
the database.
Association of age, gender, and other factors in two groups of DILI
(mitochondrial and non-mitochondrial mechanisms of toxicity)
Mitochondrial function declines with aging;13 therefore, we evaluated if reports
of severe DILI were disproportionately associated with older patient age, indicating
potential susceptibility to DILI from mitochondrial mechanisms of toxicity.
Furthermore, since gender may play an important role in the sensitivity of DILI, we also
evaluated the frequency of reports according to patient gender.

The mean and

standard deviation (SD) of patient age were calculated and compared between DILI
reports caused by drugs associated with mitochondrial mechanisms of toxicity and
DILI reports associated with non-mitochondrial mechanisms. Patient age was
dichotomized into ≤ 65 years or > 65 years for comparison. Other factors, including
drug severity class, patient weight, report type, and label section, were examined in a
descriptive analysis.
Statistical Analysis:
Descriptive statistics were used to compare the gender and age of reports for
the DILI drug groups associated with mitochondrial mechanisms of toxicity and
associated with non-mitochondrial mechanisms.

The statistical significance of

differences in categorical variables such as age group, DILI severity, drug label, and
report type between two categories of DILI drugs was examined using the chi-square
test. Whereas, differences in continuous variables such as mean patient age between
the two categories of hepatotoxic drugs were compared with the two-tailed student’s
t-test for independent samples. The unadjusted association of age and gender with
mitochondrial mechanisms of toxicity DILI group (against non-mitochondrial
mechanisms of toxicity DILI group) was determined using univariate logistic regression

56

analysis. ROR calculations were carried out using a two-by-two contingency table
using OpenEpi (version 3.01; Centers for Disease Control and Prevention), which
calculates 95% CI and p-values via Taylor series.32 Chi-square tests were performed
with SAS version 9.4 (SAS Institute, Cary, NC), and two-sided t-tests were performed
at the 0.05 significance level via GraphPad Prism version 8 (La Jolla, CA). All statistical
tests were two-sided with a significance level at 0.05.
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2.4 RESULTS
We included 192 drugs classified as having the highest DILI risk (“Most-DILI
concern”) via the NCTR-LTKB database. Out of these 192 drugs, 134 drugs had
searchable FAERS reports, while the remaining 58 drugs were either withdrawn before
our study period or were withdrawn from the European market before US approval.
Therefore, the final data set contained 134 drugs, which were categorized as 56 drugs
causing hepatotoxicity via mitochondrial mechanisms, and 78 drugs were classified as
causing hepatotoxicity via non-mitochondrial mechanisms.
Table 3 indicates the characteristics of the event reports included in the study. A
total of 104,701 adverse event reports were extracted from FAERS for the period
spanning January 1998 to May 2019. Of these, 40,343 (38.5%) reports of
hepatotoxicity were for drugs that were associated with mitochondrial mechanisms of
toxicity, whereas 64,358 (61.5%) reports of hepatotoxicity were for drugs associated
with non-mitochondrial mechanisms of toxicity. Furthermore, drugs were categorized
based on the NCTR-LTKB severity classification. There was a statistically significant
difference in DILI severity (p < 0.0001) between the two groups of DILI drugs
(mitochondrial mechanisms compared to non-mitochondrial mechanisms). There was
a 5.5 percentage point difference in reports for more severe DILI (liver
failure/hepatotoxicity) for drugs associated with mitochondrial mechanisms of toxicity
compared to non-mitochondrial mechanisms (76.3% compared to 70.8%, respectively,
p < 0.0001). As shown in Table 3, the FAERS reports were classified based on the
drug label section for liver injury; there was a statistically significant difference in drug
labels (p < 0.0001) between the two groups of DILI drugs (mitochondrial mechanisms
compared to non-mitochondrial mechanisms). Additionally, 24.6% of mitochondrial
mechanisms of toxicity drugs had a box warning label as compared to 19.8% of nonmitochondrial mechanisms of toxicity drugs, and 64.9% of mitochondrial mechanisms
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of toxicity drugs had warning and precautions label as compared to 79.1% of nonmitochondrial mechanisms of toxicity drugs.

For drugs withdrawn due to

hepatotoxicity, there were high numbers of reports (n = 4227, 10.5%) for drugs that
are associated with mitochondrial toxicity mechanisms, compared to a lower number
of reports (n = 747, 1.2%) for drugs with non-mitochondrial mechanisms of toxicity (p
< 0.0001). Over 88% of reports were expedited, while the rest of the reports were either
direct or periodic. In summary, there was a statistically significant difference between
drug severity classification, label, and liver injury severity according to the drug’s ability
to cause toxicity through mitochondrial mechanisms.
We also examined patient bodyweight, but 79%-81% of the reports did not have
this information documented. Among the 19%-21% of reports where the bodyweight
data was present, the average difference between the two groups of DILI drugs
(mitochondrial compared to non-mitochondrial mechanisms) was only 1.6 kg (68.6 ±
20.8 compared to 70.2 ± 23.4; p < 0.0001). In this case, the small p-value may be
because the large sample size overpowered the comparison. As large numbers of the
reports were missing bodyweight, further analysis was not performed. As shown in
Table 3, a higher percentage of males were the subjects of hepatotoxicity reports via
mitochondrial mechanisms compared to the subjects of reports involving
hepatotoxicity via the non-mitochondrial mechanisms (49.1% compared to 37.8%, p <
0.0001). About 7% to 8.3% of reports were missing information about the patient’s
gender.
Table 3 presents the difference in the mean and distribution of age among the two
groups. The patient’s age was recorded in more than 71% of the reports from both the
groups. As shown in Table 3, there was a statistically significant difference (p <
0.0001) between the mean age of patients with hepatotoxicity in drugs that are
associated with mitochondrial mechanisms (56.1 ± 18.33 (SD)) compared to non-
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mitochondrial mechanisms of toxicity (48 ± 19.53 (SD)). In other words, reports
involving drugs associated with mitochondrial mechanisms of hepatic toxicity
displayed a higher mean age than reports for drugs associated with non-mitochondrial
mechanisms of hepatic toxicity.
Figure 2 indicates the ROR values of drugs associated with mitochondrial
mechanisms of toxicity; benzbromarone, troglitazone, isoniazid, rifampin, and
nimesulide had the highest ROR values in the group. Figure 3 indicates the ROR
values of drugs associated with non-mitochondrial mechanisms of toxicity;
telithromycin, gemtuzumab ozogamicin, mexiletine, dactomycin, and disulfiram had
the highest ROR values in the group. Table 4 indicates the top 20 drugs with the
highest ROR values in both groups of hepatotoxicants. The top 20 drugs with the
highest ROR values included drugs with either mitochondrial or non-mitochondrial
injury mechanisms.

The top 4 drugs, which had ROR values higher than 18

(benzbromarone, troglitazone, isoniazid, rifampin), were associated with mitochondrial
mechanisms of toxicity.

Furthermore, the top two drugs, benzbromarone, and

troglitazone were withdrawn from the market.
Table 5 indicates the RORs between the two groups of drugs that caused liver
injury via mitochondrial compared to non-mitochondrial mechanisms. Between the
two DILI groups, reports for DILI involving mitochondrial mechanisms of toxicity had a
1.43 (95% CI 1.42-1.45; p < 0.0001) times higher odds compared to drugs associated
with non-mitochondrial mechanisms of toxicity. The univariate logistic regression
model was used after dichotomizing age and gender. Table 6 indicates a statistically
significant risk association of age or gender with hepatotoxic drugs with mitochondrial
toxicity mechanisms. Reports of liver injury were 2.2 (odds ratio: 2.2, 95% CI 2.122.26) times more likely to be associated with older patient age, as compared with
reports involving patients under 65 years of age. On the other hand, female patients
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were 37% less likely to be subjects of liver injury reports for drugs associated with
mitochondrial mechanisms of toxicity compared to males (Odds Ratio 0.63, 95% CI
0.61-0.64). Tables 7 to 13 contain DILI reports, all adverse event reports, ROR, and
95% Confidence Interval (CI) for all the drugs evaluated in the study.
Figure 4 indicates the totality of all ROR scores of DILI drugs with mitochondrial
or non-mitochondrial mechanisms of toxicity. Drugs from the antineoplastic, antiviral,
analgesic, antibiotic, and antimycobacterial classes were the top 5 drugs classes
associated with higher ROR scores. Drugs from the antidiabetic, antiretroviral, antiinflammatory, anti-Parkinson, vasoactive, neuroprotective, and antihyperlipidemic drug
classes (pointed in brown arrow) were primarily associated with mitochondrial
mechanisms. Alternatively, leukotriene pathway modulators, alcohol antagonists, CNS
stimulants, and platelet inhibitor drug classes (pointed in red arrow) were the drugs with
non-mitochondrial mechanisms having higher RORs. Figures 5 and 6 categorize these
two groups of drugs based on the drug label section and severity class. We did not
observe any notable trend between mitochondrial and non-mitochondrial mechanisms
and drug label section, or severity class.

61

2.5 DISCUSSION
Prediction and characterization for DILI during preclinical drug development and
post-approval remains a challenge for the pharmaceutical industry, toxicologists,
clinicians, physicians, health authorities, and regulators.5 Characterizing DILI has been
a challenge due to its unpredictability, lack of accurate biomarkers, poorly defined
pathogenesis, and its potential to cause fatal liver failure.5 In the past two decades,
drug-induced mitochondrial dysfunction has been established as an important
contributing mechanism associated with liver, muscle, heart, kidney, and central
nervous system toxicity.13 Mitochondrial dysfunction is one of the reasons known to
cause muscle toxicity by HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A)
reductase

inhibitor

(cerivastatin),

cardiovascular

toxicity

by

anthracyclines

(daunorubicin, doxorubicin, idarubicin), and DILI by an antidepressant (nefazodone),
antibiotics (isoniazid, ketoconazole(oral)), and anxiolytic (panadiplon) drugs.19, 33-36
We calculated the ROR for reports of severe hepatotoxicity adverse events
among drugs with the highest risk for DILI, for drugs having mitochondrial or nonmitochondrial mechanisms of toxicity. Brinker et al. indicated that various measures of
disproportionate reporting of adverse events such as Proportional Reporting Ratio
(PRR), Multi-item Gamma Poisson Shrinker (MGPS), and the Bayesian Confidence
Propagation Neutral Network (BCPNN) had been used in analyses of surveillance
databases.8 Each of these methods may have different strengths and limitations and
may lead to different sensitivity and specificity for a drug's risk reporting. 8 Various
health regulatory authorities use different statistical measures for reporting. For
example, the European Medicines Agency (EMA) uses PRR; FDA and UK's Medicines
and Healthcare products Regulatory Agency (MHRA) uses MGPS. Whereas, the
World Health Organization (WHO) has utilized the BCPNN method for reporting. 8
These reporting measures have been used to generate hypotheses and do not infer
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adverse event-causal associations. It has been suggested that there is not one single
measure of effect that is superior to the others. 8, 37, 38 Our study utilized reporting odds
ratios to characterize the frequency of liver injury reports as it is a straightforward and
frequently used measure for the analysis of FAERS data. 31, 39-43
The review published by Will et al.13 indicated that the most commonly used
prescriptions and over the counter medications for geriatric patients had published
reports of various toxicities linked to mitochondrial dysfunction.13 Our study reported
that reports for DILI involving mitochondrial mechanisms of toxicity had a 1.43 (95% CI
1.42-1.45; p < 0.0001) times higher odds compared to drugs associated with nonmitochondrial mechanisms of toxicity. The ROR scores with the highest risk of liver
injury based on mitochondrial or non-mitochondrial mechanisms were highest for drugs
from the antineoplastic, antiviral, analgesics, antibiotics, and antimycobacterial classes.
This finding agreed with the published literature.

Sonawane et al. indicated that

antineoplastic, analgesics, and antibiotics were among the top 10 drugs that reported
severe adverse events in the FAERS database from 2006 to 2014.26 Additionally, our
study observed that over 88% of adverse reports were expedited, while the rest of the
reports were either direct or periodic in both drug categories. This observation also
agreed with the published literature. Sonawane et al. also reported that expedited
reports were the most common and over 72% of all serious adverse events with
available data on the report type.26
Antidiabetic, antiretroviral, anti-inflammatory, anti-Parkinson, vasoactive,
neuroprotective, antihyperlipidemic drug classes were primarily associated with
mitochondrial toxicity mechanisms. In recent years, an impaired mitochondrial function
has been documented as one of the critical factors in inflammation, sarcopenia,
metabolic (obesity, type 2 diabetes, non-alcoholic fatty liver disease), and
neurodegenerative diseases (Parkinson’s, Alzheimer’s, Huntington’s diseases).13, 44-46
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Patients with reduced mitochondrial function occurring as a manifestation of their
underlying disease state may be more vulnerable to drugs that cause toxicity via
mitochondrial mechanisms.

Alternatively, antiadrenergic, leukotriene pathway

modulators, alcohol antagonist, CNS stimulants, and platelet inhibitors were drug
classes that were primarily associated with non-mitochondrial toxicity mechanisms.
We identified statistically significant differences (p < 0.0001) in drug severity
classification, label section for liver injury, and report type between these two
mechanisms for DILI. For drugs withdrawn for liver injury, there were a higher number
of hepatotoxicity reports (10.5%) associated with mitochondrial than non-mitochondrial
mechanisms (1.2%). Dykens and Will (2007) noted that 38 marketed drugs withdrew
from the market between 1994 and 2006. Among these, for cerivastatin, nefazodone,
troglitazone, and tolcapone, there was substantial evidence of mitochondrial-induced
organ toxicity.34

Therefore, our observations agreed with reports in the medical

literature of drug-induced mitochondrial dysfunction playing an important role in drug
withdrawal. Furthermore, Boelsterli and Lim (2007) suggested that several drugs, such
as amiodarone, dantrolene, diclofenac, isoniazid, lamivudine, leflunomide, mefenamic
acid, nimesulide, perhexiline, simvastatin, stavudine, sulindac, tolcapone, troglitazone,
trovafloxacin, and valproic acid, are associated with idiosyncratic DILI with a clear link
to mitochondrial toxicity.21 Many of these drugs reported a relatively higher ROR in our
study.
Our study reported an older mean patient age (56.1 ± 18.33 (SD)) associated
with reports for drugs that cause DILI via mitochondrial mechanisms compared to
mean age (48 ± 19.53 (SD)) associated with reports for drugs that cause injury via
non-mitochondrial mechanisms (p < 0.0001). This was further substantiated in a
univariate logistic regression analysis where reports of liver injury were 2.2 (odds ratio:
2.2, 95% CI 2.12-2.26) times more likely to be associated with older patient age, as
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compared with reports involving patient ages under 65 years. This finding is consistent
with physiological information indicating age as a risk factor for both mitochondrial DNA
abnormality and increased oxidative stress-related injury.45 There is evidence that
mitochondrial function declines with age, including the role of mitochondrial DNA
mutation, increased production of reactive oxygen species, and the dysfunction in
oxidative phosphorylation pathways.44 The hallmark of mitochondrial aging includes a
decreased mitochondrial number, reduced mitochondrial function, and individual
electron transport chain activities.13 Mitochondrial function deteriorates progressively
with age. Therefore, older age populations may be more vulnerable to hepatotoxic
drugs associated with mitochondrial mechanisms of toxicity.
Our study indicated that female patients were 37% less likely to report liver
injury adverse events for drugs associated with mitochondrial mechanisms of toxicity
compared to males. There are conflicting reports associating male gender as a
susceptibility factor for DILI, and a clear link for this association is absent in the
literature.

21, 47

Several articles allude to the potential involvement of a reactive

metabolite, and differences in pharmacokinetics, pharmacodynamics, sex hormones,
and immune system response between males and females.21, 22
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2.6 CONCLUSION
Mitochondria play an important part in DILI, including idiosyncratic liver injury.
There have been various proposed mechanisms for mitochondrial involvement in
DILI.45 There is a gap in the literature describing the differences in clinical outcomes
for patients who experienced DILI from mitochondrial mechanisms of toxicity as
compared with non-mitochondrial mechanisms of toxicity drugs. There are limitations
in detecting drugs that have mitochondrial liability in the drug development phase of
the discovery. For the most part, drug-induced mitochondrial toxicity does not reveal
itself in animal models due to the young age, lack of genetic divergence, health status,
and lack of concomitant drug exposure.13 Therefore, drug-induced mitochondrial
toxicity is often idiosyncratic, meaning it is not predictable until a large population is
exposed.21, 46

Based on this study, we provide evidence of a higher proportion of

reports of severe liver injury adverse events among drugs associated with
mitochondrial mechanisms of

toxicity as compared with non-mitochondrial

mechanisms of toxicity. Furthermore, we found that reports of liver injury were 2.2
(odds ratio: 2.2, 95% CI 2.12-2.26) times more likely to be associated with older patient
age, as compared with reports involving patients ages under 65 years. This finding
aligns with the theory that age is a susceptibility factor in liver injury via the
mitochondrial mechanisms of toxicity.
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2.7 LIMITATION
The FAERS database describes adverse event reports but does not include
information about the number of patients treated with a drug. Therefore, incidence
rates, prevalence rates, and causal relationships between drugs and safety adverse
events cannot be determined for drugs according to mitochondrial or nonmitochondrial mechanisms of toxicity. For example, the population incidence of DILI
may be higher for drugs associated with non-mitochondrial mechanisms than
mitochondrial mechanisms of toxicity. Nevertheless, researchers and health
authorities have used the FAERS database for adverse event signal identification,
developing ideas, and hypothesis generation despite this limitation. The hypothesis
and ideas generated using this database could serve as a foundation for more robust
study designs, and for in vitro or in vivo studies investigating the causal relationship of
a drug with liver injury. The FAERS database provides a suitable source to evaluate
the volume and characteristics of adverse event reports for marketed medications.
Furthermore, factors such as age, gender, weight, drug severity class, and label
section of FAERS reports can provide valuable insights to health authorities during the
post-market surveillance of marketed medications.
The FAERS database is a spontaneous reporting system with limitations when
used for drug safety research, including the potential for under or over-reporting events,
duplicate reports, influence of media, and uncertainty of reported events.8,
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For

example, troglitazone received significant media attention due to a class-action lawsuit
which called attention to its DILI risk. Therefore, troglitazone may have a higher
number of hepatotoxicity reports than some drugs that did not receive media attention.
Moreover, the FAERS database could be associated with the "Weber effect," where
adverse event reports are higher in initial marketing stages following a gradual decline.8
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Patients with an underlying condition such as obesity may be more vulnerable
to drugs that cause toxicity via mitochondrial mechanisms; thus, we attempted to
include patient weight in our study. However, about 79-81% of the reports missed the
bodyweight information; therefore, the effect of patient weight was not examined. The
study may also have several unmeasured confounding factors as patient comorbidities,
pre-existing liver disease, and concomitant drug use is not captured in FAERS reports.
Additionally, the findings regarding age and gender are unadjusted; therefore, it should
be used merely for hypothesis generation. Moreover, gender bias may be due to
disease demographics. Some of the DILI drugs with mitochondrial toxicity mechanisms
are prescribed for diseases with a higher male predisposition.

For example,

benzbromarone is prescribed for gout, which has six times higher occurrence in
males.49 Similarly, isoniazid and rifampin are prescribed for the treatment of
tuberculosis, which has two times higher occurrence in males.50
ROR depends on the reporting rates of liver injury adverse events and all other
adverse events reports in compared drug classes. DILI drugs associated with nonmitochondrial mechanisms of toxicity have a significantly higher number of non-hepatic
adverse events reports. Therefore, we are not sure if larger ROR values are due to
the higher reporting of hepatotoxicity in the drugs with mitochondrial mechanisms of
toxicity, or higher reporting of non-hepatic adverse events reported for the drugs with
non-mitochondrial mechanisms of toxicity.
For this analysis, we utilized ROR, which is a disproportionality measurement
of spontaneous reports and not a method to measure drug-related risks quantitatively.
Regulatory actions in response to safety concerns related to age and gender using the
FAERS database must be determined via individual cases to determine causality.
Despite these database limitations, we were able to show that drugs that cause
hepatotoxicity via mitochondrial mechanisms were associated with a higher proportion
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of adverse event reports than drugs having non-mitochondrial mechanisms of toxicity.
Additionally, age may play a role in susceptibility to DILI via mitochondrial mechanisms
of toxicity. Our findings from this study align with mitochondrial mechanisms of toxicity
being an important cause of DILI, and this should be further investigated in real-world
studies with robust designs.
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2.9 TABLES AND FIGURES
Table 1. Reporting odds ratio estimates for DILI drug groups.
Reporting odds ratio estimates for DILI drug groups
FAERS Reports (N)
All other
DILI groups
Hepatotoxicity
Adverse
Events
Drugs associated with mitochondrial
40,343
586,989
mechanisms of toxicity
Drugs associated with non64,358
1,342,486
mitochondrial mechanisms of toxicity
Total
104,701
1,929,475
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Total
627,332
1,406,844
2,034,176

Table 2. Example reporting odds ratio estimate for an individual drug:
acetaminophen.
Reporting odds ratio estimates for an individual drug
FAERS Reports (N)
All other Adverse
Hepatotoxicity
Total
Events
Acetaminophen
8,509
51,732
60,241
All other drugs of
383,540
27,852,908
28,236,448
any type
Total
392,049
27,904,640
28,296,689
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Table 3. Characteristics of patients and hepatotoxic drugs associated
with mitochondrial mechanisms of toxicity compared to nonmitochondrial mechanisms.

Characteristics of the study drugs

Characteristics

Hepatotoxicity via
Mitochondrial
mechanism (56
drugs)

Hepatotoxicity via NonMitochondrial
mechanism (78 drugs)

FAERS Report Counts (N)
40,343 (38.5%)
64,358 (61.5%)
Reports based on NKTR drug severity classification
3 - Liver aminotransferases
0 (0%)
3,048 (4.7%)
increase
4 - Hyperbilirubinemia
1,958 (4.9%)
2,292 (3.6%)
5 - Jaundice
7,526 (18.7%)
13,392 (20.8)
6 - Liver necrosis
0 (0%)
35 (0.05%)
7 -Acute liver failure
4,581 (11.3%)
17,207 (26.7%)
8 - Fatal hepatotoxicity
26,278 (65%)
28,384 (44.1)
Reports combined based on less and severe DILI
Less severe injury
9484 (23.5%)
18,767 (29.2%)
Liver failure/hepatotoxicity
30,859 (76.5%)
45,591 (70.8%)
Reports based on drug label section
Warning & precautions
Box warning
Withdrawn

26,177 (64.9%)
9,939 (24.6%)
4227 (10.5%)
Report type

50,898 (79.1%)
12,713 (19.8%)
747 (1.2%)

Direct
Expedited
Periodic

1,992 (4.9%)
35,569 (88.2%)
2,782 (6.9%)

2,393 (3.7%)
57,119 (88.8%)
4,846 (7.5%)

Patient Characteristics
FAERS Report Counts (N)
Weight Missing
Mean ± Stdev
Male
Female
Gender Missing
FAERS Report Counts (N)

Weight (Kg)
7666 (19%)
32677 (81%)
68.6 ± 20.8

13532 (21%)
50826 (79%)
70.2 ± 23.4

Gender
19,818 (49.1%)
17,711 (43.9%)
2,814 (7%)

24,353 (37.8%)
34,690 (53.9%)
5315 (8.3%)

Age (Years)
30,324 (75.2%)

46310 (71.9%)
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Age missing
Mean ± Stdev

10019 (24.8%)
56.1 ± 18.33

18046 (28%)
48 ± 19.53

A statistical difference between two DILI groups across categorical variables was
performed using a chi-square test. Comparisons of continuous variables were
performed using t-tests; P values were < 0.0001 for all the variables (P<0.05 was
considered significant)
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Table 4. Top 20 drugs with the highest reporting odds ratio in both DILI
groups.
Drug Class

Drug Name

Severity
Class

Label
Section

Mitochondrial
Toxicity

ROR

Antigout agent

Benzbromarone

8

Withdrawn

Yes

36.31

Antidiabetic agent

Troglitazone

8

Withdrawn

Yes

31.02

Antimycobacterials

Isoniazid

8

Box warning

Yes

20.79

Antimycobacterials

Rifampin

8

Yes

18.64

Antibiotics

Telithromycin

8

No

18.33

Antineoplastics

Gemtuzumab
ozogamicin

8

Box warning

No

18.08

Antiarrhythmics

Mexiletine

3

Box warning

No

17.8

Antineoplastics

Dactinomycin

8

Warnings
and
precautions

No

17.25

Anti-inflammatory
agent

Nimesulide

8

Withdrawn

Yes

15.07

Antialcoholics

Disulfiram

8

No

14.82

Antivirals

Didanosine

8

Yes

14.38

Stimulants; Central
Nervous System

Pemoline

8

Withdrawn

No

14.24

Platelet inhibitors

Ticlopidine

4

Warnings
and
precautions

No

13.51

Antibiotics

Trovafloxacin
mesylate

8

Withdrawn

Yes

13.48

Antithyroid agents

Propylthiouracil

8

Box warning

No

13.33

NSAID

Bromfenac

8

Withdrawn

No

13.01

Antiretroviral drugs

Stavudine

8

Box warning

Yes

12.83

Hormone modifiers

Danazol

8

Box warning

Yes

12.82

Antiparkinson
agents

Tolcapone

8

Box warning

Yes

12.25

Antivirals

Tipranavir

8

Box warning

No

12.04
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Warnings
and
precautions
Warnings
and
precautions

Warnings
and
precautions
Warnings
and
precautions

Table 5. Reporting odds ratio estimate for hepatotoxic drugs associated
with mitochondrial mechanisms of toxicity compared to nonmitochondrial mechanisms.
DILI group
Drugs associated with
mitochondrial mechanisms of
toxicity

Odds ratio

95% CI

p-value

1.43

1.42-1.45

<0.0001
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Table 6. Unadjusted association of age and gender with hepatotoxic
drugs with mitochondrial toxicity mechanisms as compared with nonmitochondrial mechanisms, using a univariate logistic regression model.
Independent
variable

Odds ratio

Age
<65 years
>65 years

p-value

Reference
2.2

Gender
Male
Female

95% CI

2.12-2.26

<0.0001

Reference
0.63

0.61-0.64
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<0.0001

Table 7. Adverse-event (AE) report counts and risk estimates of DILI for
analgesics, anti-adrenergic, anti-alcoholic, and antiarrhythmic
medications.

Mitochondri
al Toxicity &
Reference

DILI
reports

All AE
reports

ROR

Chlorzoxazon
e

Yes50

30

229

9.514

Analgesics

Diclofenac

Yes51, 52

350

5647

4.501

Analgesics

Diflunisal

Yes52, 53

2

60

2.421

Analgesics

Etodolac

Yes54

105

1823

4.183

Analgesics

Sulindac

Yes55

52

434

8.701

Analgesics

Indomethacin

Yes56

126

2663

3.436

No57

8509

51732

11.94

No58

6

135

3.228

Drug Class

Drug Name

Analgesics

Analgesics
Analgesics

Acetaminophe
n
Chlormezano
ne

Analgesics

Fenoprofen

No59

8

50

11.62

Analgesics

Mefenamic
acid

No11

50

391

9.287

Analgesics

Milnacipran

No*

50

2795

1.299

Antiadrenergic

Labetalol

No52

47

701

4.869

Antiadrenergic

Methyldopa

No60

116

718

11.73

Alcohol
antagonist

Disulfiram

No61

100

490

14.82

Antiarrhythmics

Amiodarone

Yes57

1590

18220

6.337

Antiarrhythmics

Dronedarone

Yes62

444

5433

5.935

Antiarrhythmics

Mexiletine

No*

125

510

17.8

95% CI
6.502,
13.92¹
4.04,
5.014¹
0.5917,
9.902
3.436,
5.092¹
6.526,
11.6¹
2.874,
4.108¹
11.67,
12.22¹
1.425,
7.311¹
5.509,
24.51¹
6.918,
12.47¹
0.9822,
1.718
3.624,
6.542¹
9.643,
14.28¹
11.95,
18.38¹
6.02,
6.671¹
5.387,
6.538¹
14.64,
21.65¹

*No literature evidence; ¹ p < 0.05 and 95% confidence limits testing exclusion
of 0 or 1, as indicated
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Table 8. Adverse-event report counts and risk estimates of DILI for
antibiotics, anticonvulsants, antidepressants, and antidiabetic
medications.

Drug Class

Drug Name

Mitochondrial
Toxicity &
Reference

DILI
reports

All AE
reports

ROR

Antibiotics

Ciprofloxacin

Yes63

1299

28830

3.272

Antibiotics

Clarithromycin

Yes64

1225

18499

4.809

Antibiotics

Nitrofurantoin

Yes52, 57

434

3044

10.35

Antibiotics

Trovafloxacin
mesylate

Yes65

1168

6291

13.48

Antibiotics

Minocycline

No*

604

4973

8.82

Antibiotics

Telithromycin

No66

1049

4157

18.33

Anticonvulsants

Carbamazepine

Yes67, 68

1606

22379

5.212

Anticonvulsants

Phenytoin

Yes67, 68

547

15593

2.548

Anticonvulsants

Valproic acid

Yes68, 69

945

11096

6.185

Anticonvulsants

Divalproex

No*

623

14095

3.21

Anticonvulsants

Felbamate

No70

18

364

3.591

Anticonvulsants

Fosphenytoin

No71

68

981

5.034

Anticonvulsants

Lamotrigine

No52

1849

45375

2.959

Antidepressant

Clomipramine

Yes72

64

1500

3.098

Antidepressant

Nefazodone

Yes14

608

4707

9.38

Antidepressant

Duloxetine

No73

2162

50955

3.081

Antidepressants

Nortriptyline

Yes74

6

1162

0.375

Acarbose

Yes75

224

1505

10.81

Troglitazone

Yes76

3047

7133

31.02

Antidiabetic
agent
Antidiabetic
agent

95% CI
3.095,
3.459¹
4.538,
5.096¹
9.363,
11.45¹
12.67,
14.35¹
8.105,
9.598¹
17.12,
19.61¹
4.954,
5.483¹
2.339,
2.774¹
5.787,
6.61¹
2.962,
3.478¹
2.237,
5.764¹
3.937,
6.436¹
2.824,
3.1¹
2.413,
3.979¹
8.62,
10.21¹
2.951,
3.217¹
0.1681,
0.8363¹
9.393,
12.44¹
29.73,
32.37¹

*No literature evidence; ¹ p < 0.05 and 95% confidence limits testing exclusion
of 0 or 1, as indicated
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Table 9. Adverse-event report counts and risk estimates of DILI for
antifungals, antigout, antihelmintic, antihyperlipidemic, antiinfectives,
anti-inflammatory, and antimycobacterial medications.

Drug Class

Drug Name

Mitochondrial
Toxicity &
Reference

DILI
reports

All AE
reports

ROR

Antifungals

Itraconazole

Yes77

566

7403

5.552

Antifungals

Ketoconazole

Yes11, 78

233

4364

3.877

Antifungals

Fluconazole

No78

920

12475

5.356

Antifungals

Griseofulvin,
Microcrystalline

No79

26

203

9.301

Antifungals

Micafungin

No80

213

1765

8.764

Antifungals

Terbinafine

No81

1330

12101

7.982

Antifungals

Voriconazole

No82

780

9093

6.229

Antigout agent

Benzbromarone

Yes52

1

2

36.31

Antigout agent

Allopurinol

No83

626

5353

8.493

Antigout agent

Febuxostat

No84

161

3910

2.99

Anthelmintics

Albendazole

Yes85

108

879

8.923

Anthelmintics

Thiabendazole

No86

5

45

8.069

Antihyperlipidemic

Gemfibrozil

Yes52, 76

267

2835

6.839

Antihyperlipidemic

Atorvastatin
calcium

Yes57

5522

89525

4.479

Antihyperlipidemic

Niacin

Yes87

219

47451

0.3352

Antiinfectives

Erythromycin

No88

154

3753

2.98

Antiinfectives

Levofloxacin

No89

1117

37160

2.183

Anti-inflammatory
agent

Nimesulide

Yes52, 57

11

53

15.07

Antimycobacterials

Isoniazid

Yes52

678

2368

20.79

Antimycobacterials

Rifampin

Yes24

1291

5029

18.64

Antimycobacterials

Ethambutol

No90

117

847

10.03

95%
CI
5.097,
6.048¹
3.398,
4.424¹
5.008,
5.727¹
6.184,
13.99¹
7.602,
10.1¹
7.542,
8.447¹
5.79,
6.702¹
3.293,
400.4¹
7.817,
9.226¹
2.554,
3.501¹
7.306,
10.9¹
3.203,
20.33¹
6.033,
7.754¹
4.358,
4.604¹
0.2935,
0.3828¹
2.536,
3.501¹
2.057,
2.317¹
7.873,
28.85¹
19.09,
22.65¹
17.54,
19.82¹
8.268,
12.17¹

¹ p < 0.05 and 95% confidence limits testing exclusion of 0 or 1, as indicated
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Table 10. Adverse-event report counts and risk estimates of DILI for
antineoplastics medications.

Drug Class

Drug Name

Mitochondrial
Toxicity &
Reference

DILI
reports

All AE
reports

ROR

Antineoplastics

Asparaginase

Yes91

145

1993

5.283

Antineoplastics

Bicalutamide

Yes52

371

4033

6.68

Antineoplastics

Erlotinib

Yes57

915

42889

1.549

Antineoplastics

Flutamide

Yes44, 52

125

807

11.25

Antineoplastics

Nilutamide

Yes76

24

259

6.729

Antineoplastics

Oxaliplatin

Yes92

1297

19069

4.939

Antineoplastics

Pazopanib

Yes93

1004

19660

3.709

Antineoplastics

Sorafenib

Yes11

3815

24782

11.18

Antineoplastics

Tamoxifen

Yes52, 76, 94

257

6330

2.948

Antineoplastics

Bexarotene

No95

14

575

1.768

Antineoplastics

Bortezomib

No96

771

24288

2.305

Antineoplastics

Busulfan

No52

625

3783

12

Antineoplastics

Cytarabine

No97

575

7603

5.492

Antineoplastics

Dacarbazine

No98

35

821

3.096

Antineoplastics

Dactinomycin

No99

200

842

17.25

Antineoplastics

Estramustine

No100

54

719

5.454

Antineoplastics

Exemestane

No101

312

6728

3.368

Antineoplastics

Gefitinib

No102

798

8074

7.178

Antineoplastics

Gemcitabine

No103

1738

25409

4.967

Antineoplastics

Gemtuzumab
ozogamicin

No104

1067

4286

18.08

Antineoplastics

Hydroxyurea

No52

129

3109

3.013

Antineoplastics

Imatinib

No11

1891

47575

2.887

No105

32

322

7.217

No11

660

14473

3.312

Antineoplastics
Antineoplastics

Interferon alfa2a,
Lapatinib
ditosylate

93

95%
CI
4.464,
6.254¹
6.006,
7.43¹
1.451,
1.654¹
9.317,
13.58¹
4.429,
10.22¹
4.669,
5.226¹
3.48,
3.952¹
10.8,
11.57¹
2.603,
3.34¹
1.041,
3.004¹
2.146,
2.477¹
11.02,
13.06¹
5.045,
5.978¹
2.207,
4.342¹
14.78,
20.13¹
4.136,
7.192¹
3.006,
3.773¹
6.674,
7.719¹
4.731,
5.215¹
16.91,
19.33¹
2.527,
3.594¹
2.757,
3.023¹
5.019,
10.38¹
3.063,
3.581¹

Antineoplastics

Mercaptopurine

No52

278

2051

9.843

Antineoplastics

Pentostatin

No*

43

403

7.749

Antineoplastics

Sunitinib

No106

2119

42918

3.586

8.684,
11.16¹
5.658,
10.61¹
3.432,
3.746¹

*No literature evidence; ¹ p < 0.05 and 95% confidence limits testing exclusion
of 0 or 1, as indicated
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Table 11. Adverse-event report counts and risk estimates of DILI for
antiparkinson, antipsoriatics, antipsychotics, antiretroviral, antithyroid,
and antiviral medications.

Drug Class

Drug Name

Mitochondrial
Toxicity &
Reference

DILI
reports

All AE
reports

ROR

Antiparkinson
agents

Tolcapone

Yes76

179

1061

12.25

Antipsoriatics

Acitretin

No107

167

2754

4.404

Antipsychotics

Clozapine

Yes14

1453

67935

1.553

Nevirapine

Yes108

1596

9761

11.87

Stavudine

Yes109

774

4382

12.83

Zidovudine

Yes109

468

4788

7.098

Methimazole

Yes110

170

1382

8.933

Propylthiouracil

No111

121

659

13.33

Antiviral

Abacavir
Sulfate

No112

812

6685

8.82

Antivirals

Didanosine

Yes113

557

2812

14.38

Antivirals

Efavirenz

Yes114

760

7903

6.984

Antivirals

Ritonavir

Yes57

880

9262

6.9

Yes115

394

21440

1.335

No116

418

4238

7.163

Antiretroviral
drugs
Antiretroviral
drugs
Antiretroviral
drugs
Antithyroid
agents
Antithyroid
agents

Antivirals
Antivirals

Peginterferon
alfa-2b
Darunavir
ethanolate

Antivirals

Etravirine

No117

145

1249

8.431

Antivirals

Interferon
alfacon-1

No*

92

1273

5.248

Antivirals

Maraviroc

No118

97

1567

4.495

Antivirals

Raltegravir
potassium

No116

414

6012

5.001

Antivirals

Tipranavir

No119

118

712

12.04

95% CI
10.46,
14.35¹
3.767,
5.148¹
1.474,
1.636¹
11.26,
12.52¹
11.88,
13.85¹
6.455,
7.805¹
7.617,
10.48¹
10.98,
16.19¹
8.20,9.48¹
13.13,
15.75¹
6.482,
7.524¹
6.438,
7.394¹
1.208,
1.474¹
6.478,
7.92¹
7.099,
10.01¹
4.247,
6.485¹
3.662,
5.519¹
4.527,
5.525¹
9.905,
14.62¹

*No literature evidence; ¹ p < 0.05 and 95% confidence limits testing exclusion
of 0 or 1, as indicated
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Table 12. Adverse-event report counts and risk estimates of DILI for
biologics, and disease-modifying antirheumatic medications.

Drug Class

Drug Name

Mitochondrial
Toxicity &
Reference

DILI
reports

All AE
reports

ROR

95% CI

Biologics

Natalizumab

No*

1804

177402

0.7385

0.7049,
0.7736¹

Carbonic
anhydrase
inhibitor

Acetazolamide

Yes68, 69

26

768

2.459

1.663,
3.634¹

Chelators

Deferasirox

No120

1933

27136

5.173

Retinoids

Isotretinoin

No*

1949

58079

2.437

Diseasemodifying
antirheumatic
drugs

Azathioprine

Yes121

549

4372

9.119

8.344,
9.966¹

Diseasemodifying
antirheumatic
drugs

Leflunomide

Yes122

1682

13795

8.855

8.417,
9.315¹

Diseasemodifying
antirheumatic
drugs

Infliximab

No*

4260

146690

2.109

2.045,
2.175¹

Diseasemodifying
antirheumatic
drugs

Methotrexate

No123

2208

31526

5.086

4.871,
5.311¹

Diseasemodifying
antirheumatic
drugs

Sulfasalazine

No124

781

7658

7.406

6.88,
7.973¹

4.939,
5.418¹
2.329,
2.55¹

*No literature evidence; ¹ p < 0.05 and 95% confidence limits testing exclusion
of 0 or 1, as indicated
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Table 13. Adverse-event report counts and risk estimates of DILI for
diuretics, gastrointestinal, hematinics, hormone modifier,
immunomodulators, leucoxene antagonists, musculoskeletal,
neuroprotective, NSAID, CNS stimulants, and vasoactive medications.

Drug Class

Drug Name

Mitochondrial
Toxicity &
Reference

DILI
reports

All AE
reports

ROR

Diuretics

Tolvaptan

No125

726

4730

11.15

Endothelin receptor
antagonist

Bosentan

No11

2125

41452

3.723

Gastrointestinal

Orlistat

No126

1335

31799

3.049

Hematinics

Eltrombopag
olamine

No127

596

10450

4.142

Hormone modifiers

Danazol

Yes52

45

255

12.82

Hormone modifiers

Oxandrolone

Yes128

12

135

6.455

Hormone modifiers

Nandrolone
decanoate

No129

15

138

7.894

Hormone modifiers

Oxymetholone

No130

17

122

10.12

Hormone modifiers

Testosterone

No131

175

30408

0.4179

No*

5343

185985

2.086

No*

2018

31442

4.661

Cyclosporine

No132

2344

39804

4.277

Zafirlukast

No*

151

1224

8.959

Zileuton

No133

28

323

6.295

Dantrolene

No134

66

570

8.409

Tizanidine

No*

133

2125

4.545

Neuroprotective

Riluzole

Yes135

75

935

5.825

NSAID

Bromfenac

No136

670

3739

13.01

Platelet inhibitors

Ticlopidine

No137

532

2860

13.51

Atomoxetine

No52

520

22207

1.7

1.559,
1.855¹

Pemoline

No138

71

362

14.24

11.04,
18.37¹

Immunomodulators
Immunomodulators
Immunosuppressives
Leukotriene pathway
modulators
Leukotriene pathway
modulators
Musculoskeletal
agents
Musculoskeletal
agents

Selective
norepinephrine
reuptake inhibitor
Stimulants; Central
Nervous System

Interferonbeta-1a
Interferon
beta-1b,
recombinant

97

95% CI
10.31,
12.05¹
3.564,
3.889¹
2.886,
3.221¹
3.813,
4.498¹
9.335,
17.59¹
3.577,
11.65¹
4.633,
13.45¹
6.093,
16.81¹
0.3602,
0.4849¹
2.03,
2.144¹
4.455,
4.876¹
4.102,
4.459¹
7.565,
10.61¹
4.279,
9.262¹
6.517,
10.85¹
3.815,
5.416¹
4.604,
7.37¹
11.99,
14.13¹
12.31,
14.82¹

Vasoactive agents

Papaverine

Yes139

2

24

6.052

1.43,
25.6¹

*No literature evidence; ¹ p < 0.05 and 95% confidence limits testing exclusion
of 0 or 1, as indicated
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Figure 1. Reporting odds ratios for hepatotoxic drugs having
mitochondrial mechanisms of DILI.
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Figure 2. Reporting odds ratios for hepatotoxic drugs having nonmitochondrial mechanisms of DILI.
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Figure 3. Sum of all ROR of “most-DILI concern” drugs associated with
mitochondrial and non-mitochondrial mechanisms of toxicity per
therapeutic class.

.
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Figure 4. Categorization based on liver injury drug label for “most-DILI
concern” drugs based on their association with mitochondrial and nonmitochondrial mechanisms of toxicity.
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Figure 5. Categorization based on liver injury severity class for “mostDILI concern” drugs based on their association with mitochondrial and
non-mitochondrial mechanisms of toxicity.
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3.1 ABSTRACT
Background
Compared to typical antipsychotics, atypical antipsychotic (AAP) drugs have improved
safety profiles and rarely cause liver injury. However, no retrospective cohort studies
have evaluated the short-term risk of liver injury associated with specific AAPs using
an administrative database in the United States.
Goal
This study aimed to identify significant risk factors of liver injury in patients taking
olanzapine, quetiapine, risperidone, or ziprasidone compared to aripiprazole. First, we
determined the cumulative incidence rate of liver injury for each AAP among newly
treated patients. Among these patients, we also investigated the association between
liver injury and type of AAP, controlling for various risk factors (age, gender, and
comorbidities)
Methods
We conducted a retrospective cohort study using an administrative claims database to
identify adults prescribed AAPs from 2010-2015. The new AAP user cohort was
selected based on a 12-months pre-index period with no AAP use, followed by a 2months AAP exposure period. ICD9 diagnosis codes were analyzed to identify liver
injuries (as a composite outcome), including liver enzyme elevation, jaundice, hepatitis,
cholestasis, cirrhosis, liver necrosis, or acute liver failure occurring during the ten
months follow-up period. The demographic and clinical characteristics of patients
prescribed AAP medications and liver injury outcome groups were examined and
adjusted for covariates. The cumulative incidence rates of liver injury among patients
taking AAP in outpatient and inpatient settings were calculated.

Univariate and

multivariate logistic regression analyses were utilized (including odds ratio, 95%
confidence interval, and p-values) to identify risk factors associated with liver injury.
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Results
Overall, the cumulative incidence rate of liver injury in various AAP therapies ranged
from 15.2 to 25.1 per 1000 persons per year. There was no significant association
between exposure to any of the AAP medications with the composite outcome. As
over 90% of the patients over the age of 76 were prescribed dosages of AAPs that
were below the daily recommended doses, a sensitivity analysis was conducted that
included only patients 75 years and younger. This analysis showed that quetiapine
was associated with 22% (adjusted Odds Ratio (aOR) 1.22, CI 1.04-1.44, p = 0.02)
increased risk of liver injury as compared with aripiprazole. Having 1 to 3 comorbidities
(aOR 1.27, CI 1.09-1.48, p = 0.003) or 4 to 10 comorbidities (aOR 1.57, CI 1.22-2.02,
p = 0.0004) was associated with 27% or 57% increased risk of liver injury as compared
with no comorbidities, respectively. Comorbidities such as documented alcohol abuse
(aOR 1.63, CI 1.27-2.08, p <0.0001), hypertension (aOR

1.46, CI 1.23-1.73, p

<0.0001), obesity (aOR 1.36, CI 1.12-1.65, p = 0.002), and hyperlipidemia (aOR 1.31,
CI 1.1-1.54, p = 0.0012) were associated with increased risk of liver injury. Anxiety
diagnosis (aOR 1.2, CI 1.03-1.38, p = 0.021) was associated with a 20% increased risk
of liver injury.
Conclusion
This retrospective cohort study determined the cumulative incidence rate of liver injury
as 15.2 to 25.1 per 1000 persons per year among patients newly treated with AAP
medications. Compared to aripiprazole, quetiapine was associated with a 22%
increased risk of liver injury during the first months of treatment in patients 75 years
and younger. Various comorbidities, including alcohol abuse, hypertension, obesity,
and hyperlipidemia, were also associated with higher odds of liver injury.
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3.2 INTRODUCTION
Drug-induced liver injury (DILI) is one of the leading reasons for clinical
candidate termination during drug discovery and development. Similarly, many drugs
have received a black-box warning or were withdrawn from the market due to DILI.1, 2
It is reported that DILI is the 4th leading cause of liver disease leading to liver failure.1
Many drug classes are associated with DILI, including nonsteroidal anti-inflammatory
drugs

(NSAID),

antiepileptic,

anti-lipidemic,

immunosuppressive, and psychotherapeutic drugs.3,

anti-infective,
4

oncology,

There has been literature

evidence of liver injury for psychotherapeutic drug class.5 Antipsychotics are broadly
categorized into two types: typical or atypical. Antipsychotic drugs, which are mainly
prescribed for psychotic disorders, including schizophrenia, psychosis, depression,
insomnia, aggression, anxiety, and bipolar disorder

6, 7

have been implicated with

clinical hepatotoxicity.5
Atypical antipsychotics (AAP) have been associated with a variety of adverse
side effects including weight gain (obesity), metabolic diseases, and nonalcoholic fatty
liver disease.8, 9 Patients treated with antipsychotic drugs such as chlorpromazine and
clozapine have increased risk of mild to severe liver injuries.10, 11 Derby et al. (1993)
conducted a cohort study of over 10,000 users of chlorpromazine in the United
Kingdom (UK).12 They reported that chlorpromazine was associated with DILI with a
frequency of 1.3/1000 users (95% CI; 0.8-2.2).12 More recently, De Abajo et al. (2004)
performed a population-based study in the United Kingdom of over 1.6 million subjects
from 1994 to 1999; they reported that chlorpromazine had the strongest association
with liver enzyme elevations, with an adjusted odds ratio (aOR) of 416 (95% CI; 453840).11

Furthermore, several case-control studies reported an association of

antipsychotics with liver injury.

10, 13

It is believed that, compared to typical

antipsychotics, atypical antipsychotics (AAP) drugs have improved safety profiles and
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only rarely cause liver injury.5

However, despite their potentially safer profile,

asymptomatic increases in transaminase liver enzymes and bilirubin have been
reported.5 When occurring, elevated liver enzymes typically appear after six weeks of
AAP treatment, and levels tend to disappear with drug withdrawal.5, 14 There are also
reports of AAP inducing liver function abnormalities in the clinical setting.6 Hence,
clinical guidelines for liver enzymes measurement during, and initiation of the AAP
drug therapy have been put in place.5
To our knowledge, there are no retrospective cohort studies that evaluated
clinical liver injury risk of AAP during the initial treatment months using a geographically
diverse US database.

This study examined the liver injury risk of various AAP

medications and liver injury risk factors among newly treated patients.

Strong

associations between liver injury and particular AAP types as identified in real-world
research such as this study, might help prescribers select appropriate AAP medications
for patients at higher risk. These study results may help clinicians understand liver
injury risks in balance with drug therapy, improve therapy adherence, and monitor for
liver injury. Furthermore, additional information about liver injury risk among AAPs is
needed to guide therapeutic monitoring protocols and more readily identify medicationrelated causes.
This study aimed to identify significant risk factors of liver injury in patients
taking olanzapine, quetiapine, risperidone, and ziprasidone compared to aripiprazole.
First, we calculated the cumulative incidence rate of liver injury among patients newly
treated with AAP medications. Then we estimated the risk of liver injury among patients
newly treated with AAPs in a multivariable framework that controlled for various risk
factors (age, sex, and comorbidities), using a retrospective cohort study based on a
nationwide insurance claims database.
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3.3 METHODS
Study design:
Data Source:
The Optum Clinformatics Data Mart (OptumInsight, Eden Prairie, MN) is an
administrative health claims database from a large national insurer. Our study
analyzed claims from January 1, 2010, to December 31, 2015. For the study, the
Optum database containing de-identified data on age, geographic location, drugs,
inpatient and outpatient services, medical services, eligibility, and pharmacy claims
were used; Institutional Review Board (IRB) approval number was IRB1920-030. The
data contain information on member eligibility, medical claims, facility detail,
prescription claims, inpatient confinement, provider, and death date. For this study,
lab results and death data were not utilized. The wide geographic representation and
size of the database serve as a valuable tool to examine liver injury risk in real-world
settings. Inpatient and outpatient medical claims included diagnosis codes based on
the International Classification of Diseases 9th (ICD9). Clinical procedures (e.g.,
laboratory testing) are recorded using the Current Procedural Terminology (CPT)
codes
Cohort selection:
Drugs under the psychotherapeutic medication class of American Hospital
Formulation Service (AHFS – 28:16 (psychotherapeutic agents)) were used for cohort
selection. AHFS – 28:16.08.04 (Atypical Antipsychotics), a pharmacologic therapeutic
classification, for AAP were used for the study cohort. The cohort included patients
who were newly treated with an AAP medication between January 1, 2011, to March
1, 2015. The index date was considered the date of the first AAP drug pharmacy claim
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following a pre-index period (spanning January 1, 2010, to January 1, 2014) of 12months without antipsychotic therapy.
Figures 1 and 2 indicate the schematic diagram of the study design and the
final cohort selection exclusion criteria, respectively. Patients were excluded from the
study if they meet any of the following criteria: 1) were prescribed any typical or atypical
antipsychotic medications in the pre-index period, 2) had less than 12-months of
continuous enrollment before and following the index period, or were not continuously
eligible for health and pharmacy benefits during the entire pre-index or exposure
periods, 3) were less than 18 years of age as of the index date, 4) had a liver injury or
HIV diagnosis at any time during their pre-index period or in the exposure period (60
days after the index date), 5) did not have at least two prescription claims for AAP
during the exposure period, 6) were dispensed chronic concomitant drugs that were
highly associated with liver injury based on LiverTox database.
Bjornsson (2016) published various drug classes that had been implicated with
DILI. The article categorized drugs from the publicly available LiverTox database
(http://livertox.nlm.nih.gov) into different groups based on their likelihood of causing
hepatotoxicity.15 Category A was DILI drugs as having more than 100 published case
reports of hepatotoxicity.15 In this study, we excluded patients prescribed chronic
concomitant medicines that had a high likelihood of causing liver injury. If the patients
were prescribed one or more category A DILI drugs with an increased liver injury
association, they were excluded from the study. The patients prescribed concomitant
drugs allopurinol, amiodarone, azathioprine, carbamazepine, dantrolene, disulfiram,
flutamide,

hydralazine,

isoniazid,

ketoconazole,

methotrexate,

methyldopa,

minocycline, phenytoin, propylthiouracil, quinidine, rifampin, sulfasalazine, ticlopidine,
valproate or valproic acid were excluded from the study.15
Exposure Definition:
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AAP medication users were defined as having received at least two
prescription claims for any quantity and duration during the exposure period. They
were monitored for liver injury diagnosis for the subsequent ten months following the
exposure period. The exposure period ended on the 60th day from the index day.
Selection of control group:
The most frequently prescribed AAPs prescribed were olanzapine, quetiapine,
risperidone, ziprasidone, and aripiprazole.

A review published by Telles-Correia

(2017) examined psychotherapeutics and liver injury, they did not describe any liver
injury reports for aripiprazole.5 Therefore, aripiprazole was used as a reference. On
the other hand, olanzapine, ziprasidone, risperidone, and quetiapine had reports of
liver enzyme elevations or other liver injuries.5
Covariates:
A variety of demographic and clinical characteristics were examined, including
patient age, gender, health plan type, geographic location, comorbidities, and disease
burden (Elixhauser comorbidity index)

16, 17

associated with the indexed prescription

during the pre-index period. Patients taking AAP may have several comorbidities;
therefore, the Elixhauser comorbidity measures could help with risk assessment of
safety data. The Elixhauser index utilizes 31 conditions using predictors of mortality
in patients with cardiac, gastrointestinal, hepatobiliary, oncologic, hypertension,
obesity, weight loss, and psychiatric conditions.18
The clinical practice guidelines from the European Association for the Study of
Liver (EASL) indicated that older age, female gender, alcohol intake, and comorbidities
(metabolic disease, chronic hepatitis) might be risk factors for DILI.19 Based on the
evidence supported by several published articles, the study investigated various
comorbidities such as hypertension, type 2 diabetes, obesity, alcohol abuse,
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hyperlipidemia, renal disease, and cardiovascular disease associated with liver injury
among patients newly treated with AAP medications.

20-23

The study included new users of AAP drug therapy only. Therefore, they are
expected to be initiated on lower doses of AAP medications. New patients are usually
prescribed low dose therapy and then gradually increase the dose based on the
effectiveness and side effects. Given that the AAP drug class has diverse
physicochemical drug properties, different drug concentrations in the human plasma
level (Cmax) are needed to achieve optimum drug effects.24 Various adult daily doses
such as 10-30 mg for olanzapine, 300-800 mg for quetiapine, 2-6 mg for risperidone,
10-30 mg for paliperidone, 10-30 mg for aripiprazole, and 80-160 mg for ziprasidone
are recommended.25
Although AAP medications were primarily approved for schizophrenia, these
drugs are also prescribed for other neuropsychiatric disorders such as bipolar disorder,
psychosis, depression, anxiety, insomnia, and aggression.7 ICD9 codes (as shown in
Table 1) were used to determine the diagnosis for AAP medications prescription for
the cohort (14 days prior and following the index day).

These diagnoses were

examined as independent variables.
Outcome Assessment:
ICD9 diagnosis codes were utilized to identify liver injuries including liver
enzyme elevation, jaundice, hepatitis, cholestasis, cirrhosis, liver necrosis, or acute
liver failure occurring during the ten months follow up period; which spanned from
March 1, 2011, to December 31, 2015. If a patient was identified with any of the ICD9
codes from Table 1, they were considered positive for the liver injury outcome. There
was one composite outcome score (yes or no) for liver injury outcome. There are
published studies for the administrative claim database utilized these diagnosis codes
to identify liver injury with high positive predictive values. 26, 27 Jinjuvadia et al. reported
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using these ICD9 codes with 53%-98% sensitivity and 59-98% accuracy.17 Bui et al.
reported positive predictive values from 48-84% for liver injury diagnosis codes.28
Sensitivity Analyses:
Sensitivity analysis to include patient’s population prescribed therapeutic doses
Patients aged 76 and older are more likely to be prescribed lower doses, and
use AAPs on an as-needed basis, for example when used for off-label indications such
as agitation or insomnia. To investigate this issue, we examined the AAP doses
prescribed among patients ages 76 and older and found that a majority received
substantially lower doses than described in the FDA label. Therefore, this population
was excluded from the study cohort in a sensitivity analysis that examined the risk of
liver injury among patients who were generally prescribed AAPs at usual recommended
doses.
Sensitivity analysis – Liver injury models based on liver enzyme exclusion and
most severe liver injury
Additional to the composite liver injury outcome, we also conducted analyses to
include only more severe forms of liver injury as the outcome, e.g., cases who had
jaundice or worse (excluding liver enzyme elevations) and the outcome of most severe
liver injury cases, including liver necrosis and acute liver failure.
Statistical Analysis:
Baseline demographic characteristics between groups were evaluated. In this
analysis, the differences of categorical variables, various demographic and clinical
characteristics, between different AAP users were compared using a chi-square test.
A comparison of a continuous variable, such as age, was performed using a student’s
t-test for independent samples. In this study, the cumulative incidence rate was
calculated by dividing the number of new cases of liver injury events in the population
over 10-months by the total number of AAP users at risk of developing a liver injury.
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The study utilized a stepwise logistic regression model via backward
elimination to choose the statistically significant independent variables associated with
liver injury. The study used univariate and multivariable analysis. The univariate
analysis evaluated the unadjusted association between the liver injury outcome and a
single variable. In contrast, the multivariable analysis assessed the adjusted
association between liver injury outcomes with several variables simultaneously. 29, 30
Before the multivariable analysis, collinearity assessment of independent variables
was performed using the variation inflation factor and condition index. Collinearity
assessment determined that there were no variables that were highly correlated
(variation inflation factor greater than 5 or conditional index greater than 30).
Model development started with a univariate logistic regression analysis
(based on liver injury outcome: no or yes) and reported odds ratios, 95% CI, and pvalues. The variables with less than 0.1 p-values were further included in the
multivariable logistic regression analysis. The AAP drug type, age, and gender were
included in the multivariable model throughout. For the rest of the covariates, a
stepwise multivariable logistic regression model via backward elimination was utilized
to choose the most statistically significant variables after removing insignificant
variables with p-value ≥ 0.05.29, 31
The Hosmer and Lemeshow goodness-of-fit test was used to determine the
performance of the model in this study. If the p-value is higher than 0.05, the model
fits appropriately with no significant difference between observed and predicted
values.30 The Area Under Curve – Receiving Operating Curve (AUC-ROC) method
was used to identify the optimal model that predicts the liver injury outcome. AUCROC is a plot of sensitivity vs. 1-specificity. 30, 32, 33 SAS version 9.4 (SAS Institute,
Cary, NC) was used to perform all the analysis, and all statistical tests were two-sided
with the 0.05 significance level.

114

3.4 RESULTS
Study cohort
As shown in Figure 2, we selected 669,972 patients prescribed AAP
medications from January 1, 2010 to December 31, 2015. We excluded 40,262
patients who were prescribed AAP medications during the pre-index period (12months before the index date),

519,863 patients

had less than 12-months of

continuous enrollment prior to or following the index period, 11,157 patients were
younger than 18 years of age, and 5,810 patients had a liver injury or HIV diagnosis
during the pre-index or exposure period. As described in the cohort selection section,
we excluded 33,465 patients who were also prescribed chronic concomitant
medications implicated in DILI during the pre-index or exposure period. Therefore,
after applying all exclusion criteria, the final cohort contains 44,414 patients who were
dispensed the most frequently used AAP medications, including quetiapine (41.4%),
aripiprazole (27.5%), risperidone (20.5%), olanzapine (8.6%), and ziprasidone (2%).
Demographic and clinical characteristics of the study population
A detailed description of demographic and clinical characteristics of the study
population is presented in Table 2 (A, B, C). Overall, more than 36% of patients were
between the ages of 41 and 65, followed by 31.3% of patients over 76. A large
proportion of the study population (66.1%) were female. Most of the patients (40.3%)
enrolled to a health maintenance organization plan, followed by 34.7% of the patients
who had a point of service plan. There were similar proportions of patients with
commercial (52.8%) and Medicare (47.2%) insurance type. Most of the patients were
in the south (43.3%) and the west (28.6%) geographic region. About 79% of patients
had diagnoses other than schizophrenia, psychosis, major depressive, bipolar
disorder, or anxiety. The top comorbidities in the study population were hypertension
(46%), hyperlipidemia (36.4%), cardiovascular disease (26%), and type 2 diabetes
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(18.7%). Approximately 45% and 9% of the patients had Elixhauser comorbidity
scores of 1-3 and 4-10, respectively, indicating that over half of the population
consisted of patients with at least one comorbidity.
Liver injury incidence rate for AAP medications
Table 3 indicates the cumulative incidence rate of liver injury in patients taking
AAP medications, combining diagnoses from outpatient and inpatient settings.
Overall, the cumulative incidence rate per 1000 persons over 10 months was 15.3.
The cumulative incidence rate of various AAP therapies ranged from 12.7 to 20.9.
Based on the cohort selected, ziprasidone had the highest incidence rate of 20.9;
alternatively, risperidone had the lowest incidence rate of 12.7 per 1000 persons over
10 months. Liver injury diagnosis was further characterized by the severity of the
injury. Overall, cholestasis or cirrhosis liver injury was the most frequent type of liver
injury reported, representing 44.8% of all types of liver injuries documented during the
follow-up period. On the other hand, liver necrosis was least frequently reported
(3.4%). Similar trends were observed for particular AAP types, where cholestasis or
cirrhosis represented 39.6% to 46.2% of documentations of liver injury, while liver
enzyme elevations ranged from 24.5% to 34.1% of documented liver injuries. Acute
liver failure, the most severe form of liver injury, represented 24.2% to 31.2% of
documented liver injuries. It is important to note here that a patient can report more
than one form of liver injury during the period observed.
Liver injury outcomes using univariate logistic regression modeling
The univariate logistic regression models were used after dichotomizing the
individual demographic variables such as age, gender, type of health plan and
insurance, and geographic region. Moreover, the comorbidities were selected based
on published research on the association of these factors with liver injury risk. The
collinearity assessment did not identify any independent variables that were highly
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collinear; therefore, all the variables were further included in univariate and
multivariable logistic regression analyses.
Table 4 includes the unadjusted odds ratios, number of patients with or without
liver injury diagnosis, 95% confidence intervals, and p-values of the univariate
regression models for liver injury outcomes. Overall, there were low numbers of cases
(1025; 2.3%) of patients with liver injury diagnosis as compared with the number of
patients without liver injury (43,389; 97.7%). Based on the model, p-values were less
than 0.1 for age, type of health plan and insurance plan, geographic region, various
diagnosis near index date, patient comorbidities, and Elixhauser comorbidity index.
Although p-values were greater than 0.1 for various AAP medications and gender, they
were included in the multivariable model given the importance of these variables to the
analysis.
Liver injury outcomes using multivariable logistic regression modeling
To determine the significant predictive variables associated with liver injury
outcome risk, a multivariable logistic regression model was applied and fitted with
independent variables, including AAP medication type, age, gender, diagnosis,
comorbidities, and Elixhauser’s comorbidity index. Health plan type, insurance type,
and geographic regions were excluded from the model as they did not show significant
associations during the multivariable model building process (p > 0.05). Similarly,
schizophrenia/psychosis diagnosis, other diagnoses near index date, type 2 diabetes
comorbidity, and renal disease comorbidities were also removed due to their lack of
statistical significance during model building (p > 0.05). As shown in figure 3 and Table
5, having 1 to 3 comorbidities (aOR 1.36, CI 1.17-1.56, p < 0.0001) or 4 to 10
comorbidities (aOR 1.59, CI 1.27-1.97, p < 0.0001) were associated with 36%, and
59% increased risk of liver injury, respectively. Similarly, comorbidities such as alcohol
abuse (aOR 1.57, CI 1.23-2.02, p = 0.0003), hypertension (aOR 1.51, CI 1.29-1.77,
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p < 0.0001), obesity (aOR 1.35, CI 1.12-1.61, p = 0.002), hyperlipidemia (aOR 1.27,
CI 1.1-1.47, p = 0.0013), and cardiovascular diseases (aOR 1.26, CI 1.08-1.47, p =
0.0027) were associated with increased risk of liver injury. Major depressive or bipolar
disorder diagnosis (aOR 1.17, CI 1.01-1.35, p = 0.032) or anxiety diagnosis (aOR 1.2,
CI 1.03-1.37, p = 0.022) was associated with 16%, and 20% increased risk of liver
injury. Patients aged 76 or older (aOR 0.45, CI 0.35-0.58, p < 0.0001) were associated
with a 55% decreased risk of liver injury. AAP therapy and gender were included in
the multivariable logistic regression model for liver injury risk; however, both variables
did not significantly associate with the outcome measured.

The Hosmer and

Lemeshow goodness-of-fit test was performed to determine if the liver injury
association model fit adequately; the model fit appropriately with a p-value of 0.09.
Furthermore, the predictive model's assessment was also conducted using ROC-AUC;
the ROC-AUC value was 0.66, indicating a good predictive model.
Daily dose distribution of AAP medications in patients ages 76 and older
Table 6 indicates the daily dose distribution of AAP medications for patients
ages 76 or older. For aripiprazole, daily recommended doses are between 10 to 30
mg, over 90% of the ≥ 76 age patients were prescribed below the daily recommended
doses (i.e., 2 and 5 mg doses). The recommended dose of olanzapine is between 10
to 20 mg daily, approximately 93% of patients age ≥ 76 were prescribed below the
daily recommended doses (i.e., 2.5 and 5 mg doses). The recommended dose of
risperidone is between 2 to 8 mg daily; over 99% of these older patients were
prescribed below the daily recommended doses (i.e., 0.25, 0.5, and 1 mg doses). The
recommended dose of ziprasidone is between 40 to 80 mg daily; over 95% of these
older patients were prescribed below or at the lower end of the daily recommended
doses (i.e., 20 and 40 mg doses). Finally, the recommended dose of quetiapine is
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between 300 to 800 mg daily, over 97% of these older patients were prescribed below
the daily recommended doses (i.e., 25 and 50 mg doses).
Sensitivity analysis – Predictive variables for liver injury outcomes in patients
75 and younger
As indicated above, >90% of the patients over the age of 76 were prescribed
below the daily recommended AAP drug doses. Therefore, in a sensitivity analysis,
we included only patients age 75 or younger using the same multivariable logistic
regression modeling approach as previously described. As shown in Table 7, in this
model quetiapine was associated with a 22% (aOR 1.22, CI 1.04-1.44, p = 0.02)
increased risk of liver injury in 75 and younger patients as compared with aripiprazole
use. Patients having 1 to 3 comorbidities (aOR 1.27, CI 1.09-1.48, p = 0.003) or 4 to
10 comorbidities (aOR 1.57, CI 1.22-2.02, p = 0.0004) were associated with 27% and
57% increased risk of liver injury, respectively. Similarly, comorbidities such as alcohol
abuse (aOR 1.63, CI 1.27-2.08, p <0.0001), hypertension (aOR 1.46, CI 1.23-1.73, p
<0.0001), obesity (aOR 1.36, CI 1.12-1.65, p = 0.002), and hyperlipidemia (aOR 1.31,
CI 1.1-1.54, p = 0.0012) were associated with increased risk of liver injury. Anxiety
diagnosis (aOR 1.2, CI 1.03-1.38, p = 0.021) was associated with a 20% increased
risk of liver injury. Based on the Hosmer and Lemeshow goodness-of-fit test, the pvalue was 0.17, and the AUC-ROC value was 0.64.
Sensitivity analysis – More restricted definitions of the liver injury outcome in
patients 75 and younger
In addition to the composite liver injury outcome, we also built separate models
based on liver injury severity. Table 8 indicates the multivariable model for composite
liver injury outcomes, excluding elevated enzymes, for the population of patients age
75 and younger. Similar to the composite liver injury outcome model, quetiapine was
associated with a 22% (aOR 1.22, CI 1.01-1.46, p = 0.036) increased risk of liver injury.
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Having 1 to 3 comorbidities (aOR 1.32, CI 1.1-1.71, p = 0.002) or 4 to 10 comorbidities
(aOR 1.78, CI 1.35-2.33, p = <0.0001) were associated with 32% and 78% increased
risk of liver injury. Similarly, comorbidities such as alcohol abuse (aOR 1.76, CI 1.352.3, p <0.0001), renal disease (aOR 1.37, CI 1.03-1.83, p = 0.03), hypertension (aOR
1.57, CI 1.31-1.89, p <0.0001), obesity (aOR 1.38, CI 1.11-1.71, p = 0.003), and
hyperlipidemia (aOR 1.29, CI 1.08-1.54, p = 0.005) were associated with increased
risk of liver injury. Major depressive or bipolar disorder diagnosis (aOR 1.26, CI 1.061.48, p = 0.007) was associated with a 26% increased risk of liver injury. Based on
the Hosmer and Lemeshow goodness-of-fit test, the p-value was 0.3, and the AUCROC value was 0.65. We also examined the most severe liver injury outcomes,
including liver necrosis and acute liver failure for patients ages 75 and younger. As
shown in Table 9, we did not observe any significant association of any particular AAPs
with the outcomes measured.
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3.5 DISCUSSION
Drug-induced liver injury is rare but can result in life-threatening liver failure,
potentially leading to death. DILI was first described over 70 years ago.34 Since then,
it has become a major concern for clinicians, the pharmaceutical industry, and health
authorities as more than 1000 drugs have been associated with liver injury. 34 Many
drug classes are associated with DILI; the antipsychotic drug class is one of them.
Typical antipsychotics were first discovered in the 1950s; whereas, atypical
antipsychotics were introduced in the 1990s.35 Current studies have reported that
there has been increased use of AAPs in recent years.36 It is generally believed that,
compared to typical antipsychotics, atypical antipsychotics have less adverse side
effects. 5, 35 Also, AAPs have better molecular toxicity profile; they are not associated
with mitochondrial mechanisms of toxicity. However, there have been reports of liver
enzymes and bilirubin elevation along with liver function abnormalities in clinical
setting.5, 6 Moreover, there is a gap in the literature evaluating the incidence and the
risk association for AAP in the real-world.
Based on the cohort selected in the study, we report that quetiapine (41.4%)
was the most frequently prescribed AAP. Our reported prescription rate agreed with a
study that examined the international trends in antipsychotic use.36 The study reported
that in 2014, quetiapine was the most frequently used AAP in all age groups in most
of the countries studied.36 Our study cohort was predominantly (>66%) female, and
over 31% of the cohort was older than 76 years. This finding was consistent with a
published report that the prevalence of antipsychotic use has increased by 15% in
people aged 65 and older.36

We reported that 79% of our cohort patients had

diagnoses other than schizophrenia, psychosis, major depressive, bipolar disorder, or
anxiety. This finding agreed with the published study by Carton et al., who reported
that up to 93% of antipsychotics could be prescribed for off-label use.37
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Based on published literature, AAP-induced severe liver toxicity is rare. TellesCorreia (2017) published a review of psychotherapeutics and liver injury, where the
authors did not report any liver injury reports for aripiprazole.5 Olanzapine, risperidone,
and quetiapine had reports of liver enzyme elevations.5 Olanzapine and risperidone
had reports of liver injury via immune mechanisms causing hepatocellular and
cholestatic lesions.5 We reported the cumulative incidence rate of 15.3 per 1000
persons over 10 months for AAP medications. Based on the cohort selected,
ziprasidone had the highest incidence rate of 20.9; alternatively, risperidone had the
lowest incidence rate of 12.7 per 1000 persons over 10 months. However, these are
rates of liver injury of patients who were prescribed AAPs; yet we do not know if the
liver injury was caused by the AAP.
To our knowledge, there were no studies that evaluated the cumulative
incidence rate of liver injury using the claims database. Liver injury diagnosis was
further characterized by the severity of the injury. Of all the liver injuries reported,
cholestasis or cirrhosis was reported most frequently at the 44.8% of all types reported,
followed by acute liver failure which represented 28.4% of documented liver injuries.
Our study reported liver enzyme elevation represented 24.5% to 34.1% of liver injury
events.

There are conflicting reports for liver injuries enzyme elevation (alanine

transaminase, aspartate transaminase, and lactate dehydrogenase) with AAP therapy.
Some reports indicated that liver enzymes' elevation is infrequent or low with AAP
agents,38,

39

whereas some studies have reported increases in transaminase liver

enzymes and bilirubin with AAP therapy.5
We evaluated AAP therapy in the multivariable logistic regression model for
liver injury risk; however, it did not significantly associate with the liver injury outcome.
We believed that it is due to the inclusion of patients 76 ages and older.

We

demonstrated that over 90% of the patients over the age of 76 were prescribed below
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the daily recommended doses for all the AAP medications. In other words, older
patients in the nursing home facility may be prescribed lower strength AAP
medications for off-label use of minor symptoms such as agitation or insomnia, and
likely use the AAP on an as-needed basis (i.e. sporadically). Several studies have
reported that off-label AAP medications use expected in about ~65% of elderly patients
(≥ 65 years) from 42 states Medicaid programs;40 additionally, 83% of Medicare claims
for AAP were associated with off-label conditions and 88% with dementia.41 Moreover,
older age patients will mostly be in a nursing home setting, which may be closely
monitored for liver enzyme elevation. They are more prone to stop AAP drug therapy
if they show an elevation in liver enzymes. Therefore, we only included patients 75 and
younger in a sensitivity analysis using multivariable logistic regression modeling. After
excluding older age patients (≥ 76 years), quetiapine was associated with a 22%
increased risk of liver injury. Similarly, the sensitivity analysis for composite liver injury
outcomes, excluding elevated enzymes for patients 75 and younger, was performed.
We found that quetiapine AAP medication was associated with a 22% increased risk
of liver injury and excluding liver enzyme elevation provided the same risk association
of quetiapine with liver injury. Liver enzyme elevations could be due to a variety of
reasons and could sometimes be transient. Elevation in liver enzymes does not
always progress to liver injury outcomes. Vatsalya et al. investigated quetiapineinduced liver injury (received 12-weeks of therapy) in heavy alcohol drinking 218
patients.42 They concluded that quetiapine did not cause liver injury (measured by liver
enzymes) in patients 18-65 years of age with pre-existing liver injury.42 Furthermore,
liver injury incidence and severity were low in quetiapine-treated patients.42 Quetiapine
is associated with mild liver enzyme elevations. However, several case-control studies
reported patients developing acute liver injury or hepatic failure after receiving
quetiapine therapy.43-46

Therefore, the evidence of the association of quetiapine-
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induced liver injury is reported in several case-control studies but lacks more extensive
studies. The published reports suggest that quetiapine-induced hepatotoxicity can be
idiosyncratic, and the mechanism is unknown.46 Based on sensitivity analysis, we did
not observe any significant association of any AAPs with the severe liver injury
outcomes, including liver necrosis and acute liver failure. We believe that the 10months of follow-up period may not be sufficient enough to observe severe liver injury
symptoms.
We investigated comorbidities such as hypertension, type 2 diabetes, obesity,
alcohol abuse, hyperlipidemia, renal disease, and cardiovascular disease associated
with a liver injury among patients newly treated with AAP medications.20-23 The clinical
practice guidelines from the European Association for the Study of Liver (EASL)
indicated that older age, female gender, alcohol intake, and comorbidities (metabolic
disease, chronic hepatitis) might be risk factors for DILI.19 Quetiapine was associated
with increased risk of DILI (for patients 75 and younger) for comorbidities; having 1 to
3 comorbidities or 4 to 10 comorbidities were associated with 27% and 57% increased
risk of liver injury. We further reported that comorbidities such as alcohol abuse (63%),
hypertension (46%), obesity (36%), and hyperlipidemia (31%) were associated with
increased risk of liver injury. Hayes et al. performed a population-based cohort study
using UK health records from 1995 to 2012 in bipolar disorder patients.47 In the study,
for ~1.5 years of drug treatment duration, there were 67% increased rates of 15%
weight gain in 1376 patients taking quetiapine (hazard ratio (HR) 1.67, 95% CI 1.242.20, p <0.001).47 Hayes et al. did not observe a statistically significant difference in
hepatoxicity in quetiapine treatment than lithium.47 In contrast, compared to lithium,
quetiapine was associated with lower risk of kidney and endocrine adverse events
(kidney disease HR 0.62, 95% CI 0.47–0.80, p < 0.001; hypercalcemia HR 0.23, 95%
CI 0.07–0.73, p = 0.013).47
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Ucok et al. indicated that AAP medication users are associated with a higher
risk of weight gain, new-onset of diabetes mellitus, hyperlipidemia, prolongation of the
QTc interval of the electrocardiogram, myocarditis, sexual dysfunction, extrapyramidal
side effects, and new-onset of cataracts.20 Meyer and Koro (2004) published a review
indicating that quetiapine (along with olanzapine and clozapine) has been associated
with a higher risk of hyperlipidemia.48 Atmaca et al. showed that quetiapine was
associated with increased triglyceride levels in a 6-week prospective study of
schizophrenia patients (11.64 ± 4.56 mg/dl, p < 0.05).49 Centorrino et al. indicated that
patients taking psychotropic medications had a higher prevalence of metabolic
comorbidities than the general population (37% compared to 30%; p < 0.0001).21
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3.6 CONCLUSION
This retrospective cohort study determined the cumulative incidence rate of liver
injury 15.2 to 25.1 per 1000 persons per year among patients newly treated with AAP
medications. Compared to aripiprazole, quetiapine was associated with a 22%
increased risk of liver injury during the first months of treatment in patients 75 years
and younger. We propose further prospective real-world studies to substantiate these
findings. We propose that patients on quetiapine AAP should be monitored for liver
enzyme elevations as an early sign of liver injury.

Finally, patients with various

comorbidities such as alcohol abuse, hypertension, obesity, and hyperlipidemia, should
be monitored closely for liver injury when they are prescribed AAPs.
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3.7 LIMITATION
The study used an administrative claims database where the data was collected
mainly for claim purposes; thus, billing and coding errors may be present. Studies
utilizing claims database could be relatively inexpensive; however, there is no control
over the types of data collected. Therefore, there may be insufficient or inadequate
information on exposures, outcomes, and confounders. Observational retrospective
cohort studies such as ours are a less robust design than randomized control trials due
to potential inherent biases; therefore, a causality of scientific mechanism-based
hypothesis for an AAP-induced liver injury was not possible. Additionally, increased
risk or association does not imply causation. Further study(is) may be necessary to
evaluate these factors' predictive nature using more robust methodologies and in
vitro/in vivo mechanistic toxicity studies. Medical claims databases do not contain
information on potential risk factors such as illicit drug use, over-the-counter drug use,
and smoking; these additional potential risk factors remain unknown.50 Finally, using
the claims database allowed drug use assessment based mainly on pharmacy claims;
the real use patterns of medication use was unknown.
The study contains fixed exposure and follow up period as we planned to
evaluate AAP treatment during initial stages where doses are low. We intended to
examine the differential risk of liver injury during the treatment initiation phase and not
over a longer time. This short-term analysis is adequate as there is no time between
exposure and outcome; it will enable us to evaluate the temporal relationship between
exposure and outcome. However, fixed exposure and follow-up period could cause
selection bias. Moreover, it is possible that a patient could have a liver injury after one
or two months of follow up period and could discontinue the treatment. If patients
switched to different AAP within the 60-days exposure period, they were excluded from
the study. However, if a patient switched to different antipsychotic drugs outside 60-
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days of the exposure period, their outcome was attributed to the AAP initially
prescribed. The study assessed the cumulative incidence rate of liver injury between
AAP among new users with various comorbidities.

Therefore, the underlined

comorbidities influencing liver injury in the new AAP users cannot be ruled out. From
the Optum database, liver function tests were not available; hence, quantitative
elevation in hepatic enzyme levels was not investigated. This study only assessed
short term outcomes (10-months); therefore, the long-term prognosis of drug-induced
hepatotoxicity and chronic hepatopathy were not evaluated. This information could add
value to the study, as in many cases, short-term liver enzyme elevations could be
reversed and may not necessarily result in long-term liver damage. Moreover, there
are limitations of using only ICD9 codes to identify adverse events such as liver injury,
which have poor sensitivity and may lead to underreporting of liver injuries.26 Junjuvadia
et al. (2007) recommended combining a text search of the dictated medical record with
ICD9 codes to identify liver injury adverse events in an administrative claims database.
26
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3.9 TABLES AND FIGURES
Table 1. Literature references and diagnosis terms for the ICD9 codes
used in the study.
Literature Reference
Jinjuvadia et al.26; Udo et al. 51
Forns et al.52

Diagnosis Term
Jaundice
Nonspecific elevation of
transaminase or lactate
dehydrogenase
Acute and subacute necrosis of
liver
Liver failure, not otherwise
specified

ICD9 codes
277.4
790.4

Jinjuvadia et al.26; Lo Re et al. 27Udo
570.x
et al. 51; Bui et al. 28 Forns et al.52
Jinjuvadia et al.26; Lo Re et al. 27 Udo
572.8
et al. 51
53
54
Schmidt et al. ; Kramer et al. ; Liu
571.2, 571.5,
Cirrhosis
et al.55
571.6
26
51
Jinjuvadia et al. ; Udo et al. Lo Re
Jaundice, hepatocellular or
573.3
et al. 27; Bui et al. 28; Forns et al.52
Hepatitis
Jinjuvadia et al.26
Cholestasis
576.8
Jinjuvadia et al.26; Bui et al. 28
Jaundice alone
782.4
Lo Re et al. 27; Udo et al. 51Bui et al. Acute liver failure, hepatic coma,
572.2, 572.4,
28
; Forns et al.52
hepatitis
573.8, and V42.7
51
Udo et al.
Unspecified disorder of the liver
573.9
Dietz et al.56
042,079.53,
HIV diagnosis
795.71, V08
Meller et al.57; Lau et al.58
Obesity
V85.xx, 278
Klompas et al.59; Hux et al.60; Wang
Diabetes mellitus (type 2)
250.x0, 250.x2
et al.61
Franklin et al. 62; Wang et al.61;
Hyperlipidemia
272.0-272.4
Lambert et al.23
Wang et al.61
Hypertension
401.xx-405.xx
Du Cheyron et al.63; Moreau et al.64;
403.xx, 404.xx,
Renal disease
Liu et al.55; Wang et al.61
580.xx – 588.xx
Wang et al.61
420.xx-429.xx;
Cardiovascular disease
433.xx-434.xx
Issak et al.65
Alcohol abuse
305.0
66
23
Cloutier et al. ; Lambert et al. ; Litz
Schizophrenia
295.00-295.99
et al 67
Gardner et al.68; Litz et al 67
296.00-296.09,
Major depressive disorder/bipolar 296.10-296.19,
disorder (MDDBP)
296.40-296.80,
296.20-296.39
Litz et al 67
300.00-300.99,
Anxiety disorder
309.00-309.99
Litz et al 67
301.00-301.99,
Personality disorder
301.20-301.99
Litz et al 67
Other psychosis
297.00-299.99
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Table 2A. Demographic and clinical characteristics of patients
prescribed atypical antipsychotic drugs.
Demographic and clinical characteristics of patients prescribed atypical
antipsychotic drugs
Aripiprazole
(N=12214;
27.5%)

Olanzapine
(N=3833;
8.6%)

Quetiapine
(N=18404;
41.4%)

Risperidone
(N=9062;
20.4%)

65.9 (20.4)

619 (16.2%)
1426
(37.2%)

63.54 (20.4)
3964
(16.1%)
5621
(30.5%)
2410
(13.1%)
6409
(40.3%)
11694
(63.5%)
6710
(36.5%)

Ziprasidone
(N=901;
2%)

Total
(N=444
14;
100%)

Age (Years)

2309 (25.5%)

50.3
(17.88)
277
(30.7%)
438
(48.6%)

1206 (13.3%)

89 (9.9%)

4244 (46.8%)

97 (10.8%)

8676
(19.5%)
16370
(36.7%)
5447
(12.3%)
13921
(31.3)

3177 (35.1%)

629
(69.8%)
272
(30.2%)

29349
(66.1%)
15065
(33.9%)

8351
(45.4%)

4575 (50.5%)

256
(28.4%)

188 (4.9%)

942 (5.1%)

377 (4.2%)

74 (8.2%)

116 (1%)

113 (3%)

627 (3.4%)

320 (3.5%)

5 (0.5%)

PPO

751 (6.2%)

239 (6.2%)

1321 (7.2%)

647 (7.1%)

POS

6801 (55.7%)

1033 (27%)

5161 (28%)

2013 (22.2%)

54 (6%)
419
(46.5%)

Other

515 (4.2%)

339 (8.8%)

2002 (11%)

1130 (12.5%)

93 (10.3%)

17886
(40.3%)
2829
(6.4%)
1181
(2.7%)
3012
(6.8%)
15427
(34.7%)
4092
(9.1%)

Mean (SD)
18-40
(reference)

49.15 (16.4)

63.72 (19.6)

3577 (29.3%)

41-65

6789 (55.4%)

555 (14.5%)
1233
(32.2%)

66-75

1123 (9.2%)

≥76

745 (6.1%)

Gender
Female
(reference)

8692 (71.2%)

Male

3522 (28.8%)

2449
(63.9%)
1384
(36.1%)

Health plan
HMO
(reference)

2783 (22.8%)

1921
(50.1%)

EPO

1248 (10.2%)

IND

1303 (14.4%)

5885 (64.9%)

HMO, Health Maintenance Organization; EPO, Exclusive Provider Organization; PPO,
Preferred Provider Organization; POS, Point of Service; Bold values represent p-value less
than 0.05 exposed vs. non-exposed (Statistical difference between different AAP users and
various demographic and clinical characteristics groups on a categorical variable were
performed using a chi-square test, and a comparison of all the continuous variables were
performed using t-tests)
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Table 2B. Demographic and clinical characteristics of patients
prescribed atypical antipsychotic drugs.
Demographic and clinical characteristics of patients prescribed atypical
antipsychotic drugs

Type of
insurance
Commercial
(reference)
Medicare
Geographic
region
Northeast
(reference)
Midwest
West
South
Diagnosis
near index
date
Schizophreni
a/Psychosis
Major
depressive/b
ipolar
disorder
Anxiety
Others
diagnosis

Aripiprazole
(N=12214;
27.5%)

Olanzapine
(N=3833;
8.6%)

Quetiapine
(N=18404;
41.4%)

Risperidone
(N=9062;
20.4%)

Ziprasidone
(N=901;
2%)

Total
(N=4441
4; 100%)

9745
(79.8%)
2469
(20.2%)

1620
(42.3%)
2213
(57.7%)

8240
(44.8%)
10164
(55.2%)

3281
(36.2%)
5781
(63.8%)

582
(64.6%)
319
(35.4%)

23468
(52.8%)
20946
(47.2%)

1094 (9%)

267 (7%)

2683 (22%)
2491
(20.4%)
5946
(48.7%)

769 (20%)
1398
(36.5%)
1399
(36.5%)

1545 (8.4%)
3400
(18.5%)

7774 (42%)

742 (8.2%)
1739
(19.2%)
2981
(32.9%)
3600
(39.7%)

48 (5.3%)
191
(21.2%)
163
(18.1%)
499
(55.4%)

3696
(8.3%)
8782
(19.8%)
12718
(28.6%)
19218
(43.3%)

714 (6%)

598 (15.6%)

1768 (9.6%)

1447 (16%)

174
(19.3%)

4701
(10.6%)

3006
(16.3%)
3607
(19.6%)
14797
(80.4%)

1709
(18.9%)
1611
(17.8%)
7451
(82.2%)

344
(38.2%)
220
(24.4%)
681
(75.5%)

9930
(22.4%)
9366
(21.1%)
35048
(78.9%)

4106
(33.6%)
3207
(26.3%)
9007
(73.7%)

765 (20%)
721 (18.8%)
3112
(81.2%)

5685 (31%)

Bold values represent p-value less than 0.05 exposed vs. non-exposed (Statistical
difference between different AAP users and various demographic and clinical
characteristics groups on a categorical variable were performed using a chi-square test,
and a comparison of all the continuous variables were performed using t-tests)
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Table 2C. Demographic and clinical characteristics of patients
prescribed atypical antipsychotic drugs.
Demographic and clinical characteristics of patients prescribed atypical
antipsychotic drugs
Aripiprazole
(N=12214;
27.5%)

Olanzapine
(N=3833;
8.6%)

Quetiapine
(N=18404;
41.4%)

Risperidone
(N=9062;
20.4%)

Ziprasidone
(N=901;
2%)

Total
(N=44414;
100%)

1319 (11%)

228 (6%)

1233
(6.7%)

596 (6.6%)

127
(14.1%)

3513
(7.9%)

2065
(22.8%)
3569
(39.4%)

208
(23.1%)
327
(36.3%)

1089 (12%)
4850
(53.5%)
2910
(32.1%)

53 (6%)
404
(44.8%)
207 (23%)

340 (4%)

60 (6.6%)

8312
(18.7%)
16181
(36.4%)
3805
(8.6%)
20790
(46.8%)
11526
(26%)
1809
(4.1%)

360 (40%)
457
(50.7%)

20471
(46.1%)
19951
(44.9%)

84 (9.3%)

3992 (9%)

Patients with
comorbidities
Obesity
Diabetes
mellitus (type
2)

1780
(14.6%)
3987
(32.6%)
498 (4.1%)
4449
(36.4%)
1897
(15.5%)

727 (19%)
1407
(36.7%)
391
(10.2%)
1882
(49.1%)
1099
(28.7%)

475 (4%)

148 (4%)

1-3

5676
(46.5%)
5795
(47.5%)

1799
(46.9%)
1666
(43.5%)

4-10

743 (6.1%)

368 (9.6%)

Hyperlipidemia
Renal disease
Hypertension
Cardiovascular
disease
Alcohol abuse
Elixhauser
comorbidity
index
0

3532
(19.2%)
6891
(37.4%)
1774
(9.6%)
9205
(50.0%)
5413
(29.4%)
786
(4.3%)

8493
(46.2%)
8098
(44%)
1813
(9.9%)

4143
(45.7%)
3935
(43.4%)
984
(10.9%)

Bold values represent p-value less than 0.05 exposed vs. non-exposed (Statistical
difference between different AAP users and various demographic and clinical
characteristics groups on a categorical variable were performed using a chi-square test,
and a comparison of all the continuous variables were performed using t-tests)
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Table 3. Cumulative incidence of liver injury rate in patients prescribed
atypical antipsychotic drugs.

Number of
diagnosis
reported
liver injury
diagnoses
(No)
Liver injury
diagnosis
(Yes)
Liver
enzyme
elevation
only
Jaundice or
hepatitis
Cholestasis
or cirrhosis
Liver
necrosis
Acute liver
failure
Cumulative
incidence
rate (per
1000 person
over 10
months)

Aripiprazole

Olanzapine

Quetiapine

Risperidone

Ziprasidone

Total

18043

6483

30647

15191

1484

71848

17722
(98.2%)

6392
(98.6%)

30186
(98.5%)

14998
(98.7%)

1453
(97.9%)

70751
(98.5%)

321 (1.78%)

91 (1.4%)

461 (1.5%)

193 (1.3%)

31 (2.1%)

1097
(1.5%)

87 (27.1%)

31 (34.1%)

113
(24.5%)

49 (25.4%)

10 (32.3%)

290
(26.4%)

70 (21.8%)

15 (16.5%)

35 (18.1%)

6 (19.4%)

141 (43.9%)

36 (39.6%)

89 (46.1%)

13 (41.9%)

12 (3.7%)

5 (5.5%)

10 (2.2%)

7 (3.6%)

3 (9.7%)

37 (3.4%)

100 (31.2%)

22 (24.2%)

130
(28.2%)

51 (26.4%)

9 (29%)

312
(28.4%)

17.80

14.03

15.00

12.70

20.90

15.30

107
(23.2%)
213
(46.2%)
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233
(21.2%)
492
(44.8%)

Table 4. Number of patients with or without liver injury diagnosis,
unadjusted odds ratio, 95% confidence interval, and p-values of
independent variables for liver injury outcome using univariate logistic
regression modeling.

Independent
variables

No liver
injury

Total

43389
(97.7%)

1025 (2.3%)

11914
(27.5%)

300 (29.3%)

Liver injury

Odds
ratio
estimates

Confidence
Intervals

*p-value

AAP medications
Aripiprazole
Olanzapine

Reference

3750 (8.6%)
17971
(41.4%)

83 (8.1%)

0.88

0.69-1.12

433 (42.4%)

0.96

0.82-1.11

Risperidone

8880 (20.5%)

182 (17.8%)

0.81

0.68-0.98

Ziprasidone

874 (2%)

27 (2.6%)

1.22

0.82-1.83

8504 (19.6%)
15863
(36.6%)

172 (16.8%)
508 (49.6%)

1.58

1.33-1.89

5287 (12.2%)
13736
(31.7%)

160 (15.6%)

1.5

1.2-1.9

185 (18.1%)

0.66

0.54-0.82

Quetiapine

0.125

Age (Years)
18-40
41-65
66-75
≥76

Reference
<0.0001*

Gender
Female
Male
Type of health
plan

28695
(66.1%)
14695
(33.9%)

654 (63.8%)
371 (36.2%)

Reference
1.11

0.12

0.97-1.26

HMO

17529
(40.4%)

357 (34.8%)

EPO

2758 (6.4%)

71 (6.9%)

1.26

0.98-1.64

IND

1159 (2.7%)

22 (2.2%)

0.93

0.6-1.44

PPO

96 (9.4%)

1.62

1.29-2.03

POS

2916 (6.7%)
15041
(34.7%)

386 (37.7%)

1.26

1.09-1.46

Other

3986 (9.2%)

93 (9.1%)

1.15

0.9-1.44

22885
(52.7%)

583 (56.9%)

Reference

0.0005*

Type of Insurance
Commercial
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Reference

0.0088*

20504
(47.3%)

442 (43.1%)

Northeast

3593 (8.3%)

103 (10.1%)

Midwest

8581 (19.8%)
12485
(28.8%)
18730
(43.2%)

201 (19.6%)

Medicare
Geographic
region

West

0.85

0.75-0.96

Reference
0.82

0.64-1.04
<0.0001*

233 (22.7%)

0.65

0.52-0.82

488 (47.6%)

0.91

0.73-1.13

4543 (10.5%)

158 (15.4%)

1.56

1.31-1.85

<0.0001*

9611 (22.2%)

319 (31.1%)

1.59

1.39-1.82

<0.0001*

Anxiety
Others/diagnosis
not documented
Patients
comorbidities
(yes)

9069 (20.9%)
34320
(79.1%)

297 (29%)

1.54

1.35-1.77

<0.0001*

728 (71%)

0.65

0.57-0.74

<0.0001*

Obesity
Diabetes mellitus
(type 2)

3362 (7.8%)

151 (14.7%)

2.06

1.73-2.45

<0.0001*

8037 (18.5%)
15672
(36.1%)

275 (26.8%)

1.61

1.4-1.86

<0.0001*

509 (49.6%)

1.75

1.54-1.98

<0.0001*

3692 (8.5%)
20162
(46.5%)
11182
(25.7%)

113 (11%)

1.33

1.09-1.63

0.0045*

628 (61.3%)

1.82

1.61-2.07

<0.0001*

344 (33.6%)

1.46

1.28-1.66

<0.0001*

1728 (4%)

81 (7.9%)

2.07

1.64-2.61

<0.0001*

South
Diagnosis near
index date (yes)
Schizophrenia/Psy
chosis
Major
depressive/bipolar
disorder

Hyperlipidemia
Renal disease
Hypertension
Cardiovascular
disease
Alcohol abuse
Elixhauser
comorbidity index
0
1-3

20133
(46.4%)
19402
(44.7%)

338 (33%)
549 (53.6%)

Reference
1.69

1.47-1.93

<0.0001*

4-10
3854 (8.9%)
138 (13.5%)
2.13
1.75-2.61
*All the variables where p-values are less than 0.1 were included to build a multivariable
model
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Table 5. Adjusted odds ratio, 95% confidence interval, and p-values of
independent variables for liver injury outcome using a multivariable
logistic regression model.
Multivariable logistic regression analysis of independent variables for
liver injury outcome

AAP therapy

Gender
Age

Diagnosis

Comorbidity

Independent variables

Odds ratio

95% CI

p-value

Olanzapine
Quetiapine
Risperidone

1.05
1.16
1.01

0.82-1.35
0.99-1.36
0.83-1.23

0.7
0.06
0.92

Ziprasidone

1.13

0.76-1.69

0.55

Male

1.03

0.9-1.18

0.64

Age 41-65
Age 66-75
Age ≥76
Major
depressive/bipolar
disorder
Anxiety

1.15
0.92
0.45

0.95-1.39
0.72-1.18
0.35-0.58

0.14
0.52
<0.0001

1.17

1.01-1.35

0.032

1.19

1.03-1.37

0.022

Obesity

1.35

1.12-1.61

0.002

Hyperlipidemia

1.27

1.1-1.47

0.0013

Hypertension
Cardiovascular
disease
Alcohol abuse

1.51

1.29-1.77

<0.0001

1.26

1.08-1.47

0.0027

1.57

1.23-2.0

0.0003

Elixhauser
1 to 3
1.36
1.17-1.56
<0.0001
comorbidity
4 to10
1.59
1.27-1.98
<0.0001
index
Bold values indicate statistically significant (p-value less than 0.05) variables.
Reference categories for the variable were: Elixhauser score of zero, no
comorbidity, no diagnosis, age group 18-40, female gender, and aripiprazole AAP
therapy. Hosmer and Lemeshow goodness-of-fit test p-value was 0.09. ROC-AUC
value was 0.66.
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Table 6. Dose distribution of atypical antipsychotic drugs in patients
ages 76 and older.
Aripiprazole (N=1475; 5.6%); Daily
recommended dose - 10-30 mg

Olanzapine (N=2192; 8.4%); Daily
recommended dose - 10-20 mg

Doses

Patients prescribed

Doses

Patients prescribed

2 mg

927 (62.9%)

2.5 mg

1349(61.5%)

5 mg

413 (28%)

5 mg

686 (31%)

10 mg

62 (4.2%)

7.5 mg

13 (0.6%)

15 mg

23 (1.6%)

10 mg

130 (5.9%)

20 mg

5 (0.34%)

15 mg

9(0.4%)

30 mg

24 (1.63%)

20 mg

5 (0.23%)

Risperidone (N=8574; 32.7%); Daily
recommended dose - 2-8 mg

Ziprasidone (N=356; 1.4%); Daily
recommended dose - 40-80 mg twice

Doses

Patients prescribed

Doses

Patients prescribed

0.25 mg

3851 (44.9%)

20 mg

206 (57.9%)

0.5 mg

3656 (42.6%)

40 mg

131 (36.8%)

1 mg

854 (10%)

60 mg

4 (1.2%)

3 mg

11 (0.13%)

80 mg

15 (4.2%)

Quetiapine (N=13589; 51.9%); Daily
recommended dose - 300-400 mg
Doses

Patients prescribed

25 mg

11391 (84.4%)

50 mg

1898 (14%)

100 mg

191 (1.4%)

150 mg

114(0.8%)

200 mg

101 (0.74%)

300 mg
23 (0.17%)
Bold values indicate the highest % of
prescribed doses.
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Table 7. Sensitivity analysis - adjusted odds ratio, 95% confidence
interval, and p-values of independent variables for liver injury outcome
for patients 75 and under.
Multivariable logistic regression analysis of independent variables for liver
injury outcome for patients 75 and younger

AAP therapy

Gender
Age

Diagnosis

Comorbidity

Elixhauser
comorbidity index

Independent
variables

Odds ratio

95% CI

p-value

Olanzapine

1.12

0.85-1.47

0.42

Quetiapine

1.22

1.04-1.44

0.02

Risperidone

1.06

0.85-1.31

0.6

Ziprasidone

1.25

0.84-1.88

0.27

Male

1.05

0.91-1.22

0.48

Age 41-65

1.18

0.97-1.43

0.09

Age 66-75

0.95

0.74-1.23

0.7

Major
depressive/bipolar
disorder

1.16

1.0-1.35

0.05

Anxiety

1.17

1.0-1.36

0.05

Obesity

1.36

1.12-1.65

0.002

Hyperlipidemia

1.31

1.11-1.54

0.0012

Hypertension

1.46

1.23-1.73

<0.0001

Alcohol abuse

1.63

1.27-2.08

<0.0001

1 to 3

1.27

1.09-1.48

0.003

4 to10

1.57

1.22-2.02

0.0004

Bold values indicate statistically significant (p-value less than 0.05) variables. Reference
categories for the variable were: Elixhauser score of zero, no comorbidity, no diagnosis,
age group 18-40, female gender, and aripiprazole AAP therapy. Hosmer and Lemeshow
goodness-of-fit test p-value was 0.17. ROC-AUC value was 0.64.
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Table 8. Sensitivity analysis - adjusted odds ratio, 95% confidence
interval, and p-values of independent variables for composite liver injury
outcome (excluding liver enzyme elevation) for patients 75 and under.
Multivariable logistic regression analysis of independent variables for
composite liver injury outcome excluding elevated enzymes for patients
75 and younger

AAP therapy

Gender
Diagnosis

Comorbidity

Elixhauser
comorbidity
index

Independent variables

Odds ratio

95% CI

p-value

Olanzapine

0.94

0.68-1.29

0.69

Quetiapine

1.22

1.01-1.46

0.036

Risperidone

1.02

0.8-1.29

0.89

Ziprasidone

1.14

0.7-1.81

0.59

Male

0.99

0.84-1.16

0.87

Major
depressive/bipolar
disorder

1.26

1.06-1.48

0.007

Obesity

1.38

1.11-1.71

0.003

Hyperlipidemia

1.29

1.08-1.54

0.005

Hypertension

1.57

1.31-1.89

<0.0001

Renal disease

1.37

1.03-1.82

0.03

Alcohol abuse

1.76

1.35-2.3

<0.0001

1 to 3

1.32

1.1-1.71

0.002

4 to 10

1.78

1.35-2.33

<0.0001

Bold values indicate statistically significant (p-value less than 0.05) variables. Reference
categories for the variable were: Elixhauser score of zero, no comorbidity, no diagnosis,
age group 18-40, female gender, and aripiprazole AAP therapy. Hosmer and Lemeshow
goodness-of-fit test p-value was 0.3. ROC-AUC value was 0.65.

145

Table 9. Sensitivity analysis - adjusted odds ratio, 95% confidence
interval, and p-values of independent variables for severe liver injury
outcome including liver necrosis and acute liver failure for patients 75
and under.

Multivariable logistic regression analysis of independent variables for
severe liver injury outcome including liver necrosis and acute liver
failure for patients 75 and younger
Independent variables

Odds ratio

95% CI

p-value

Olanzapine

0.87

0.52-1.45

0.58

Quetiapine

1.06

0.78-1.43

0.71

Risperidone

0.77

0.51-1.16

0.21

Ziprasidone

1.48

0.76-2.87

0.24

Gender

Male

0.92

0.71-1.2

0.54

Insurance

Medicare

1.53

1.1-2.1

0.01

Midwest

0.56

0.36-0.86

0.008

West

0.52

0.33-0.81

0.004

South

0.58

0.4-0.84

0.004

Major depressive/bipolar
disorder

1.39

1.06-1.8

0.017

Hyperlipidemia

1.41

1.06-1.87

0.017

Renal disease

1.68

1.08-2.6

0.02

Cardiovascular disease

1.39

1.02-1.89

0.04

AAP therapy

Region

Diagnosis

Comorbidity

Bold values indicate statistically significant (p-value less than 0.05) variables.
Reference categories for the variable were: no comorbidity, no diagnosis, commercial
insurance, northeast region, female gender, and aripiprazole AAP therapy. Hosmer
and Lemeshow goodness-of-fit test p-value was 0.8. ROC-AUC value was 0.65.
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Figure 1. Schematic diagram of the study design.
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Figure 2. Inclusion and exclusion criteria for cohort selection.
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Figure 3. Adjusted odds of liver injury associated with AAP use and
other risk factors

*AAP therapy - Olanzapine
*AAP therapy - Quetiapine
*AAP therapy - Risperidone
*AAP therapy - Ziprasidone
*Gender - Male
*Age - 41-65
*Age - 66-75
Age -  76
Diagnosis - depressive/bipolar disorder (yes)
Diagnosis - Anxiety (yes)
Comorbidity - Obesity (yes)
Comorbidity - Hyperlipidemia (yes)
Comorbidity - Hypertension (yes)
Comorbidity - Cardiovascular disease (yes)
Comorbidity - Alcohol abuse (yes)
*Elixhauser score - 1-3
Elixhauser score - 4-10
0.0

0.5

1.0
1.5
Adjusted Odds Ratio

2.0

2.5

*P-value was greater than 0.05. Reference categories for the variable were: AAPs
were compared with aripiprazole as reference group; Elixhauser score of zero, no
comorbidity, no diagnosis, age group 18-40, female gender, and aripiprazole AAP
therapy. Hosmer and Lemeshow goodness-of-fit test p-value was 0.09. ROC-AUC
value was 0.66.
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